[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1116
1. Fritz MA, Sade B, Bauer TW, Wood BG, Lee JH: Benign fibrous histiocytoma of the pterygopalatine fossa with intracranial extension. Acta Neurochir (Wien); 2006 Jan;148(1):73-6; discussion 76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign fibrous histiocytoma of the pterygopalatine fossa with intracranial extension.
  • Despite the histologic absence of nuclear pleomorphism, the tumor rapidly recurred after complete surgical resection.
  • The aggressive nature of our patient's tumor confirms previous observations that an aggressive radiographic appearance has prognostic value when dealing with skeletal and soft tissue tumors.
  • In the subset of fibrous histiocytomas that invade bone, however adjunctive treatment with radiation and or chemotherapy may be appropriate.
  • [MeSH-major] Brain / pathology. Histiocytoma, Benign Fibrous / pathology. Neoplasm Recurrence, Local / pathology. Palate, Hard. Skull Base Neoplasms / pathology
  • [MeSH-minor] Fatal Outcome. Humans. Male. Middle Aged. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16200478.001).
  • [ISSN] 0001-6268
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


2. Li Y, Dang TA, Shen J, Perlaky L, Hicks J, Murray J, Meyer W, Chintagumpala M, Lau CC, Man TK: Identification of a plasma proteomic signature to distinguish pediatric osteosarcoma from benign osteochondroma. Proteomics; 2006 Jun;6(11):3426-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of a plasma proteomic signature to distinguish pediatric osteosarcoma from benign osteochondroma.
  • Osteosarcoma (OS) is the most common malignant bone tumor in children.
  • To identify a plasma proteomic signature that can detect OS, we used SELDI MS to perform proteomic profiling on plasma specimens from 29 OS and 20 age-matched osteochondroma (OC) patients.
  • Nineteen statistically significant ion peaks that were differentially expressed in OS when compared with OC patients were identified (p < 0.001 and false discovery rate < 10%).
  • Using the proteomic profiles, we constructed a multivariate 3-nearest neighbors classifier to distinguish OS from OC patients with a sensitivity of 97% and a specificity of 80% based on external leave-one-out crossvalidation.
  • The higher plasma level of SAA in OS patients was further validated by Western blotting when compared to that of osteochrondroma patients and normal subjects as reference.
  • The classifier based on this plasma proteomic signature may be useful to differentiate malignant bone cancer from benign bone tumors and for early detection of OS in high-risk individuals.
  • [MeSH-major] Biomarkers, Tumor / blood. Blood Proteins / analysis. Bone Neoplasms / metabolism. Osteosarcoma / metabolism. Proteome / analysis
  • [MeSH-minor] Adolescent. Adult. Child. Diagnosis, Differential. Humans. Osteochondroma / diagnosis. Protein Array Analysis. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

  • Genetic Alliance. consumer health - Osteochondroma.
  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16673437.001).
  • [ISSN] 1615-9853
  • [Journal-full-title] Proteomics
  • [ISO-abbreviation] Proteomics
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA81465
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Blood Proteins; 0 / Proteome
  •  go-up   go-down


3. Sachanandani NS, Brown JM, Zaidman C, Brown SS, Mackinnon SE: Intraneural perineurioma of the median nerve: case report and literature review. Hand (N Y); 2010 Sep;5(3):286-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intraneural perineurioma is a benign peripheral nerve sheath tumor of perineurial cell origin.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Muscle Nerve. 2004 Aug;30(2):239-43 [15266642.001]
  • [Cites] Neurosurg Clin N Am. 2004 Apr;15(2):177-92 [15177317.001]
  • [Cites] Expert Rev Neurother. 2005 Jul;5(4):515-23 [16026235.001]
  • [Cites] South Med J. 2005 Jul;98(7):750-1 [16108251.001]
  • [Cites] Curr Opin Neurol. 2005 Oct;18(5):604-10 [16155448.001]
  • [Cites] Eur Radiol. 2007 Nov;17(11):2880-8 [17447070.001]
  • [Cites] Clin Neurophysiol. 2007 Jun;118(6):1410-6 [17466584.001]
  • [Cites] Neurosurg Focus. 2007;22(6):E23 [17613215.001]
  • [Cites] Neurosurg Focus. 2007;22(6):E26 [17613218.001]
  • [Cites] Neurosurg Focus. 2007;22(6):E6 [17613223.001]
  • [Cites] Arch Pathol Lab Med. 2007 Sep;131(9):1382-92 [17824794.001]
  • [Cites] J Clin Neuromuscul Dis. 2007 Sep;9(1):243-7 [17989587.001]
  • [Cites] Adv Anat Pathol. 2008 May;15(3):147-64 [18434767.001]
  • [Cites] Zentralbl Neurochir. 2008 Aug;69(3):134-8 [18666052.001]
  • [Cites] Joint Bone Spine. 2008 Dec;75(6):643-9 [18823807.001]
  • [Cites] Neurosurg Clin N Am. 2008 Oct;19(4):517-31, v [19010278.001]
  • [Cites] Neurosurg Clin N Am. 2008 Oct;19(4):573-81, vi [19010282.001]
  • [Cites] Neurosurg Clin N Am. 2008 Oct;19(4):583-95, vi [19010283.001]
  • [Cites] Neurosurg Focus. 2009 Feb;26(2):E12 [19416056.001]
  • [Cites] Schweiz Rundsch Med Prax. 1979 Jun 5;68(23):731-5 [450882.001]
  • [Cites] Cancer. 1978 May;41(5):1823-9 [647630.001]
  • [Cites] Schweiz Rundsch Med Prax. 1977 Feb 15;66(7):189-91 [834728.001]
  • [Cites] Muscle Nerve. 1992 Dec;15(12):1364-8 [1470202.001]
  • [Cites] Am J Surg Pathol. 1992 Aug;16(8):756-63 [1497116.001]
  • [Cites] Muscle Nerve. 1991 Apr;14(4):335-41 [1851247.001]
  • [Cites] Acta Neuropathol. 1989;77(5):514-8 [2655369.001]
  • [Cites] Hum Pathol. 1988 Dec;19(12):1455-7 [2847973.001]
  • [Cites] Plast Reconstr Surg. 1988 Feb;81(2):251-8 [3336657.001]
  • [Cites] Neurosurgery. 1986 Jul;19(1):134-8 [3748334.001]
  • [Cites] Arch Pathol Lab Med. 1984 Jul;108(7):557-60 [6329127.001]
  • [Cites] J Ultrasound Med. 1984 Nov;3(11):505-7 [6439894.001]
  • [Cites] Am J Clin Pathol. 1995 Jun;103(6):696-704 [7785653.001]
  • [Cites] Cancer Genet Cytogenet. 1993 Mar;66(1):1-10 [8467468.001]
  • [Cites] Clin Radiol. 1997 Jan;52(1):8-17 [9022574.001]
  • [Cites] J Bone Joint Surg Am. 1997 Sep;79(9):1398-401 [9314404.001]
  • [Cites] Neurosurgery. 1998 Jul;43(1):78-83 [9657192.001]
  • [Cites] Muscle Nerve. 1999 Jan;22(1):28-36 [9883854.001]
  • [Cites] J Clin Ultrasound. 1999 Sep;27(7):363-8 [10440783.001]
  • [Cites] Plast Reconstr Surg. 2000 May;105(6):2089-91 [10839408.001]
  • [Cites] J Neurosurg. 2001 May;94(5):811-5 [11354415.001]
  • [Cites] Eur Radiol. 2002 Jan;12(1):44-55 [11868073.001]
  • [Cites] Eur Radiol. 2002 Sep;12(9):2352-64 [12195495.001]
  • [Cites] Neuroradiology. 2003 Mar;45(3):166-70 [12684721.001]
  • [Cites] Radiographics. 2003 Nov-Dec;23(6):e15 [12939473.001]
  • [Cites] J Neurol Sci. 1964 Jul-Aug;1(4):340-7 [14192576.001]
  • [Cites] AJR Am J Roentgenol. 2004 Mar;182(3):741-4 [14975979.001]
  • [Cites] J Neurooncol. 2004 Aug-Sep;69(1-3):335-49 [15527099.001]
  • (PMID = 19876692.001).
  • [ISSN] 1558-9455
  • [Journal-full-title] Hand (New York, N.Y.)
  • [ISO-abbreviation] Hand (N Y)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2920385
  •  go-up   go-down


Advertisement
4. Hristov B, Shokek O, Frassica DA: The role of radiation treatment in the contemporary management of bone tumors. J Natl Compr Canc Netw; 2007 Apr;5(4):456-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of radiation treatment in the contemporary management of bone tumors.
  • Multiple studies have established a role for radiotherapy as a definitive local treatment of unresectable lesions or when surgery might yield unacceptable functional outcomes, such as in Ewing's tumor or base of skull chondrosarcoma.
  • In the metastatic setting, external beam radiotherapy and bone-seeking intravenous radioisotopes are used on a case-by-case basis for palliation.
  • As radiotherapy and its delivery techniques have evolved, so has its role in treating tumors such as Ewing's sarcoma, chordoma and chondrosarcoma, osteosarcoma, primary lymphoma of bone, malignant fibrous histiocytoma of bone, and vascular tumors.
  • Radiation can also be successfully used to treat unresectable or recurrent benign tumors, such as giant cell tumor and aneurysmal bone cyst.
  • This article reviews the indications for radiotherapy for various bone tumors and summarizes some of the important data supporting its use.
  • [MeSH-major] Bone Neoplasms / radiotherapy. Osteosarcoma / radiotherapy. Sarcoma, Ewing / radiotherapy

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17442236.001).
  • [ISSN] 1540-1405
  • [Journal-full-title] Journal of the National Comprehensive Cancer Network : JNCCN
  • [ISO-abbreviation] J Natl Compr Canc Netw
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 66
  •  go-up   go-down


5. Capodiferro S, Maiorano E, Giardina C, Lacaita MG, Lo Muzio L, Favia G: Osteoblastoma of the mandible: clinicopathologic study of four cases and literature review. Head Neck; 2005 Jul;27(7):616-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Osteoblastoma is a benign bone tumor accounting for 1% of all bone tumors; it commonly involves the spine and the sacrum of young individuals, with less than 5% being localized to the posterior mandible.
  • METHODS: A retrospective study of four benign osteoblastomas was performed based on a review of the clinical, radiographic, and histopathologic features of all cases.
  • RESULTS: The tumors involved the posterior mandible of young patients (age range, 10-21 years; two male and two female patients) and appeared as painful bone expansions.
  • Histologically, they were composed of osteoid and woven bone surrounded by plump osteoblast-like cells with interposed fibroblasts, inflammatory cells, and red blood cells.
  • CONCLUSIONS: Osteoblastomas may be distinguished from other bone tumors, fibro-osseous lesions, and odontogenic neoplasms on the basis of integrated clinical, radiologic, and histologic features and usually manifest an indolent clinical course.
  • [MeSH-minor] Adolescent. Adult. Child. Diagnosis, Differential. Female. Humans. Male. Retrospective Studies. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15880408.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 20
  •  go-up   go-down


6. Yamaguchi T, Watanabe-Ishiiwa H, Suzuki S, Igarashi Y, Ueda Y: Incipient chordoma: a report of two cases of early-stage chordoma arising from benign notochordal cell tumors. Mod Pathol; 2005 Jul;18(7):1005-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incipient chordoma: a report of two cases of early-stage chordoma arising from benign notochordal cell tumors.
  • Chordomas are rare malignant bone tumors primarily involving both ends of the axial skeleton that present as destructive bone lesions with a large soft tissue mass.
  • However, recent studies suggest the possibility that chordomas arise from benign notochordal cell tumors.
  • The coccygeal tumors were composed of intraosseous and extraosseous infiltrative lesions.
  • The intraosseous lesions consisted of both benign notochordal cell tumor and incipient chordoma.
  • In addition, two other small benign notochordal cell tumors were found at a different level in case 1.
  • It is conceivable that pre-existing intraosseous benign notochordal cell tumors transform into incipient chordoma and then extend through the cortex into the surrounding soft tissue.
  • The incidence of incipient chordoma appears much higher than expected because chordomas are rare tumors with an incidence of one case per 1 000 000 persons per year.
  • [MeSH-minor] Aged. Aged, 80 and over. Carcinoma, Hepatocellular / complications. Coccyx. Fatal Outcome. Humans. Liver Neoplasms / complications. Male. Neoplasm Staging. Notochord / pathology. Prostatic Neoplasms / complications

  • Genetic Alliance. consumer health - Chordoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15803192.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Franceschi F, Marinozzi A, Rizzello G, Papalia R, Rojas M, Denaro V: Computed tomography-guided and arthroscopically controlled en bloc retrograde resection of a juxta-articular osteoid osteoma of the tibial plateau. Arthroscopy; 2005 Mar;21(3):351-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Osteoid osteoma represents approximately 10% to 11% of all the benign bone tumors.
  • The lesion was removed by a rear-entry computed tomography (CT)-guided drill under arthroscopic control and the bony defect filled with bone graft harvested from the proximal tibial metaphysis.
  • The follow-up CT scan 2 years after surgery showed complete excision of the lesion and perfect positioning of the bone graft.
  • [MeSH-major] Arthroscopy / methods. Bone Neoplasms / surgery. Knee Joint / surgery. Osteoma, Osteoid / radiography. Osteoma, Osteoid / surgery. Tibia / surgery. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15756191.001).
  • [ISSN] 1526-3231
  • [Journal-full-title] Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association
  • [ISO-abbreviation] Arthroscopy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Xiao H, Gong S, Nie X, Guo C, Zhong G: [Ossifying fibroma of the temporal bone]. Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2006 Oct;20(19):868-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ossifying fibroma of the temporal bone].
  • OBJECTIVE: To describe the clinical presentation of ossifying fibroma of the temporal bone, and to discuss its diagnosis and treatment.
  • METHOD: A rare case of ossifying fibroma of the temporal bone was presented.
  • Frozen section evaluation during operation was not definitive but suggested benign nature in histology.
  • The tumor was fully resected.
  • RESULT: The final pathological report indicated the stromal cells were negative for S-100 protein and epithelia membrane antigen (EMA), supporting the diagnosis of ossifying fibroma.
  • One-year follow-up showed the sealed EAC was satisfactory with complete interior and no tumor recurred.
  • CONCLUSION: Ossifying fibroma of the temporal bone is a rare entity, which is a benign neoplasm but may show an aggressive behavior by compression and encroachment upon adjacent structures.
  • [MeSH-major] Bone Neoplasms. Fibroma, Ossifying. Temporal Bone / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17168109.001).
  • [Journal-full-title] Lin chuang er bi yan hou ke za zhi = Journal of clinical otorhinolaryngology
  • [ISO-abbreviation] Lin Chuang Er Bi Yan Hou Ke Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


9. Skubitz KM, Manivel JC: Giant cell tumor of the uterus: case report and response to chemotherapy. BMC Cancer; 2007;7:46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant cell tumor of the uterus: case report and response to chemotherapy.
  • BACKGROUND: Giant cell tumor (GCT) is usually a benign but locally aggressive primary bone neoplasm in which monocytic macrophage/osteoclast precursor cells and multinucleated osteoclast-like giant cells infiltrate the tumor.
  • The etiology of GCT is unknown, however the tumor cells of GCT have been reported to produce chemoattractants that can attract osteoclasts and osteoclast precursors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Giant Cell Tumors / drug therapy. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Angiogenesis Inhibitors / administration & dosage. Antibiotics, Antineoplastic / administration & dosage. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Antineoplastic Agents, Alkylating / administration & dosage. Bevacizumab. Combined Modality Therapy. Doxorubicin / administration & dosage. Female. Humans. Hysterectomy. Ifosfamide / administration & dosage. Lung Neoplasms / diagnosis. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 1992 Feb;158(2):331-4 [1729794.001]
  • [Cites] APMIS Suppl. 1991;23:113-8 [1883635.001]
  • [Cites] Cancer. 1993 Nov 15;72(10):2963-9 [8221562.001]
  • [Cites] Clin Orthop Relat Res. 1994 May;(302):219-30 [8168305.001]
  • [Cites] Am J Clin Oncol. 1995 Apr;18(2):144-8 [7900706.001]
  • [Cites] Pathol Int. 1996 Sep;46(9):656-60 [8905874.001]
  • [Cites] Clin Orthop Relat Res. 1997 Feb;(335):253-61 [9020226.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2378-84 [9196153.001]
  • [Cites] Cell. 1998 Apr 17;93(2):165-76 [9568710.001]
  • [Cites] Surg Neurol. 1998 May;49(5):547-52 [9586934.001]
  • [Cites] J Cell Biochem. 1998 Jul 1;70(1):121-9 [9632113.001]
  • [Cites] J Clin Oncol. 1998 Jul;16(7):2445-51 [9667262.001]
  • [Cites] Int Orthop. 1998;22(3):200-4 [9728318.001]
  • [Cites] Pediatrics. 1999 Jun;103(6 Pt 1):1282-3 [10353942.001]
  • [Cites] Rev Chir Orthop Reparatrice Appar Mot. 1999 Jun;85(3):293-6 [10422135.001]
  • [Cites] J Exp Med. 1999 Jul 19;190(2):293-8 [10432291.001]
  • [Cites] J Cancer Res Clin Oncol. 1999 Oct;125(10):577-81 [10473871.001]
  • [Cites] Cancer. 2005 Jul 15;104(2):361-6 [15948172.001]
  • [Cites] J Clin Oncol. 2001 Aug 1;19(15):3483-9 [11481354.001]
  • [Cites] Am J Clin Pathol. 2002 Feb;117(2):210-6 [11863217.001]
  • [Cites] Cancer. 2002 Jun 15;94(12):3225-9 [12115355.001]
  • [Cites] Clin Orthop Relat Res. 2002 Aug;(401):202-8 [12151897.001]
  • [Cites] J Oral Maxillofac Surg. 2002 Oct;60(10):1103-11; discussion 1111-3 [12378481.001]
  • [Cites] Cancer Invest. 2003 Apr;21(2):167-76 [12743981.001]
  • [Cites] Life Sci. 2003 Aug 1;73(11):1427-36 [12850503.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):158-65 [12909228.001]
  • [Cites] Br J Surg. 2004 Feb;91(2):242-7 [14760675.001]
  • [Cites] Orthopade. 2004 Mar;33(3):344-8 [15007559.001]
  • [Cites] Skeletal Radiol. 2004 May;33(5):295-9 [14997349.001]
  • [Cites] J Lab Clin Med. 2004 Aug;144(2):78-91 [15322502.001]
  • [Cites] Clin Orthop Relat Res. 2004 Sep;(426):32-8 [15346048.001]
  • [Cites] Clin Orthop Relat Res. 2004 Sep;(426):103-9 [15346059.001]
  • [Cites] Clin Cancer Res. 2004 Sep 1;10(17):5732-40 [15355900.001]
  • [Cites] Calcif Tissue Int. 2004 Jul;75(1):71-7 [15037971.001]
  • [Cites] J Lab Clin Med. 2004 Oct;144(4):193-200 [15514587.001]
  • [Cites] Cancer. 1968 Aug;22(2):333-44 [5660199.001]
  • [Cites] Endocrinology. 1972 Oct;91(4):916-20 [5051344.001]
  • [Cites] Cancer. 1973 Mar;31(3):621-5 [4693590.001]
  • [Cites] Cancer. 1975 Aug;36(2):495-504 [50874.001]
  • [Cites] Science. 1975 Nov 21;190(4216):784-5 [1105786.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1976 Sep 21;371(3):199-217 [184582.001]
  • [Cites] Acta Pathol Microbiol Scand A. 1981 Mar;89(2):179-84 [7270164.001]
  • [Cites] Cancer. 1981 Nov 1;48(9):2022-8 [7296510.001]
  • [Cites] Arkh Patol. 1983;45(2):78-82 [6847417.001]
  • [Cites] J Bone Joint Surg Am. 1985 Jul;67(6):890-900 [4019539.001]
  • [Cites] Nature. 1999 Nov 18;402(6759):304-9 [10580503.001]
  • [Cites] Am J Pathol. 2000 Mar;156(3):761-7 [10702390.001]
  • [Cites] J Bone Miner Res. 2000 Apr;15(4):640-9 [10780856.001]
  • [Cites] Hum Pathol. 2000 Jul;31(7):804-12 [10923916.001]
  • [Cites] Eur J Cancer. 2001 May;37(7):870-7 [11313175.001]
  • [Cites] J Pathol. 1985 Nov;147(3):153-8 [4067733.001]
  • [Cites] Gynecol Oncol. 1986 Mar;23(3):381-6 [3957125.001]
  • [Cites] J Clin Invest. 1987 Feb;79(2):483-91 [3027126.001]
  • [Cites] Clin Orthop Relat Res. 1988 Dec;(237):275-85 [3056645.001]
  • [Cites] Clin Orthop Relat Res. 1989 Jun;(243):208-15 [2656024.001]
  • [Cites] Cancer. 1990 Apr 15;65(8):1838-42 [2317762.001]
  • [Cites] J Cancer Res Clin Oncol. 1993;119(5):301-3 [8440744.001]
  • (PMID = 17359524.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibiotics, Antineoplastic; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents, Alkylating; 2S9ZZM9Q9V / Bevacizumab; 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  • [Number-of-references] 57
  • [Other-IDs] NLM/ PMC1832205
  •  go-up   go-down


10. Rodríguez Paramás A, Lendoiro Otero C, González García JA, Souviron Encabo R, Scola Yurrita B: [Temporal bone chondroblastoma. A clinical case and literature review]. Acta Otorrinolaringol Esp; 2006 Aug-Sep;57(7):336-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Temporal bone chondroblastoma. A clinical case and literature review].
  • [Transliterated title] Condroblastoma de hueso temporal. Caso clínico y revisión de la literatura.
  • After radiologic diagnosis, intraoperatory biopsy and surgical removal, the anatomopathological result confirmed the histology of chondroblatoma, with a satisfactory postoperative evolution.
  • The chondroblastoma is a benign bone tumor typically located in the epiphysis of long bones and the temporal bone is an excepcional location as we have verified through a literature review.
  • [MeSH-major] Chondroblastoma. Skull Neoplasms. Temporal Bone

  • Genetic Alliance. consumer health - Chondroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17036998.001).
  • [ISSN] 0001-6519
  • [Journal-full-title] Acta otorrinolaringológica española
  • [ISO-abbreviation] Acta Otorrinolaringol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 9
  •  go-up   go-down


11. Okada K, Ito K, Yamasoba T, Ishii M, Iwasaki S, Kaga K: Benign mass lesions deep inside the temporal bone: imaging diagnosis for proper management. Acta Otolaryngol Suppl; 2007 Dec;(559):71-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign mass lesions deep inside the temporal bone: imaging diagnosis for proper management.
  • CONCLUSION: Among mass lesions inside the temporal bone, benign tumors and cholesteatomas can be differentiated by contrast enhancement in T1-weighted images (T1WI) and by diffusion-weighted images (DWI).
  • OBJECTIVES: To review the imaging characteristics of mass lesions inside the temporal bone and to investigate pertinent imaging modalities for differential diagnosis, which is crucial for appropriate treatment planning.
  • PATIENTS AND METHODS: This was a retrospective case series study of six patients seen between 2002 and 2005 with mass lesions deep inside the temporal bone.
  • RESULTS: One patient had facial schwannoma, two had glomus jugulare tumor, and three had cholesteatoma.
  • MRI study provided us with better clues: contrast enhancement on T1WI was observed only in benign tumors and only cholesteatomas showed high intensity on DWI.
  • [MeSH-major] Cholesteatoma, Middle Ear. Cranial Nerve Neoplasms / diagnosis. Cranial Nerve Neoplasms / surgery. Facial Nerve. Glomus Jugulare Tumor / diagnosis. Granuloma / diagnosis. Granuloma / surgery. Mucocele / diagnosis. Neurilemmoma / diagnosis. Neurilemmoma / surgery. Temporal Bone
  • [MeSH-minor] Angiography. Diagnosis, Differential. Diffusion Magnetic Resonance Imaging. Humans. Male. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18340574.001).
  • [ISSN] 0365-5237
  • [Journal-full-title] Acta oto-laryngologica. Supplementum
  • [ISO-abbreviation] Acta Otolaryngol Suppl
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


12. Sadeghi-Azandaryani M, Mendl N, Rademacher A, Hoffmann U, Steckmeier B, Heyn J: Pseudoaneurysm of the popliteal artery due to osteochondroma of the distal femur. Vasa; 2010 Aug;39(3):274-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Osteochondroma is the most common type of benign bone tumour, and is most often found in the knee region.
  • The lesion is usually clinically silent although it may cause different complications such as fractures of the tumour, bone deformities, neurological disorders, malignant transformation and in rare cases vascular disorders.
  • A delay in diagnosis especially of pseudoaneurysm formation may result in life-threatening situations, extensive operations and lengthy hospital stays.

  • Genetic Alliance. consumer health - Osteochondroma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20737389.001).
  • [ISSN] 0301-1526
  • [Journal-full-title] VASA. Zeitschrift für Gefässkrankheiten
  • [ISO-abbreviation] VASA
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


13. Geniets C, Vanhoenacker FM, Van de Perre S, Van Dyck P, Gielen J, De Schepper AM, Parizel PM: Proceedings of the European Society of Musculoskeletal Radiology (ESSR) training module, Antwerp, 20-21.01.05. Part two: bone tumors. Benign bone lesions: characteristic imaging features. JBR-BTR; 2006 Sep-Oct;89(5):266-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proceedings of the European Society of Musculoskeletal Radiology (ESSR) training module, Antwerp, 20-21.01.05. Part two: bone tumors. Benign bone lesions: characteristic imaging features.
  • Benign bone lesions are a fairly common finding in radiology practice.
  • Often, the combination of patient's age and plain radiographic findings are sufficient for diagnosis and obviates the need for further imaging.
  • Generally the following parameters should be assessed in the evaluation of a bone lesion: clinical features, age of the patient, location, size, pattern of bone destruction, cortical involvement, zone of transition, sclerotic margination and matrix calcification.
  • This article reviews the spectrum of clinical and imaging appearances of the most common benign bone tumors.
  • [MeSH-major] Bone Diseases / diagnosis. Bone Neoplasms / diagnosis. Magnetic Resonance Imaging. Radiology. Societies, Medical. Tomography, X-Ray Computed
  • [MeSH-minor] Bone and Bones / pathology. Humans

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Diseases.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17147017.001).
  • [ISSN] 0302-7430
  • [Journal-full-title] JBR-BTR : organe de la Société royale belge de radiologie (SRBR) = orgaan van de Koninklijke Belgische Vereniging voor Radiologie (KBVR)
  • [ISO-abbreviation] JBR-BTR
  • [Language] eng
  • [Publication-type] Congresses
  • [Publication-country] Belgium
  •  go-up   go-down


14. Decock CE, Kataria S, Breusegem CM, Van Den Broecke CM, Claerhout IJ: Ectopic meningioma anterior to the lacrimal gland fossa. Ophthal Plast Reconstr Surg; 2009 Jan-Feb;25(1):57-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 66-year-old man reported a slowly growing tumor on the lateral edge of his left upper eyelid.
  • A neoplasm of the lacrimal gland was suspected.
  • Resection of the tumor was performed, which was located just behind the orbital septum and in front of the lacrimal gland.
  • Anatomopathologic investigation of the excised specimen with immunohistochemistry revealed a benign meningioma of a meningotheliomatous type, containing multiple bone elements.
  • Therefore, it should be included in the differential diagnosis of a lacrimal gland tumor.

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19273931.001).
  • [ISSN] 1537-2677
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mucin-1; 0 / Vimentin
  •  go-up   go-down


15. Benoit MM, Handzel O, McKenna MJ, Deschler DG: A 42-year-old man with facial nerve weakness and multiple recurrent pleomorphic adenoma. Otol Neurotol; 2010 Sep;31(7):1157-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To describe a case and discuss the differential diagnosis of facial nerve paresis presenting years after resection of multiple recurrent parotid pleomorphic adenoma.
  • MAIN OUTCOME MEASURES: Histopathologic diagnosis and treatment outcome.
  • RESULTS: Final diagnosis of recurrent pleomorphic adenoma causing compression of the facial nerve at the stylomastoid foramen.
  • CONCLUSION: Facial nerve weakness caused by a benign salivary gland tumor is rare.
  • [MeSH-minor] Adult. Humans. Immunosuppressive Agents / therapeutic use. Magnetic Resonance Imaging. Male. Neoplasm Recurrence, Local. Temporal Bone / pathology. Tomography, X-Ray Computed

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20657328.001).
  • [ISSN] 1537-4505
  • [Journal-full-title] Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
  • [ISO-abbreviation] Otol. Neurotol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


16. Kuroda K, Tajima S: Proliferation of HSP47-positive skin fibroblasts in dermatofibroma. J Cutan Pathol; 2008 Jan;35(1):21-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSIONS: Skin fibroblast is one of the major constituent cells in DF, and DF may be composed chiefly of two types of cell lineages, fibroblasts and bone marrow-derived monocyte/macrophages (dermal dendritic cells and/or histiocytes).
  • [MeSH-major] Fibroblasts / metabolism. HSP47 Heat-Shock Proteins / metabolism. Histiocytoma, Benign Fibrous / metabolism. Skin / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Adult. Antigens, CD / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. Biomarkers, Tumor / metabolism. Cell Count. Cell Lineage. Cell Nucleus / pathology. Cell Proliferation. Dendritic Cells / metabolism. Dendritic Cells / pathology. Factor XIIIa / metabolism. Female. Giant Cells / metabolism. Giant Cells / pathology. Histiocytes / metabolism. Histiocytes / pathology. Humans. Male

  • Genetic Alliance. consumer health - Dermatofibroma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18095990.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Biomarkers, Tumor; 0 / CD68 antigen, human; 0 / HSP47 Heat-Shock Proteins; 0 / SERPINH1 protein, human; EC 2.3.2.13 / Factor XIIIa
  •  go-up   go-down


17. Albores-Saavedra J, Grider DJ, Wu J, Henson DE, Goodman ZD: Giant cell tumor of the extrahepatic biliary tree: a clinicopathologic study of 4 cases and comparison with anaplastic spindle and giant cell carcinoma with osteoclast-like giant cells. Am J Surg Pathol; 2006 Apr;30(4):495-500
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant cell tumor of the extrahepatic biliary tree: a clinicopathologic study of 4 cases and comparison with anaplastic spindle and giant cell carcinoma with osteoclast-like giant cells.
  • We report four previously undescribed primary giant cell tumors of the extrahepatic biliary tree and morphologically compare them with 10 anaplastic spindle and giant cell carcinomas with osteoclast-like giant cells of the gallbladder.
  • Two giant cell tumors were located in the distal common bile duct; one in the cystic duct and one in the gallbladder.
  • The 3 patients with bile duct tumors were male, and the only patient with a gallbladder tumor was a female.
  • The patients with bile duct tumors presented with biliary obstruction, and the patient with a gallbladder tumor presented with symptoms of cholelithiasis and a gallbladder mass.
  • Histologically, the tumors were similar to giant cell tumors of bone.
  • The benign osteoclast-like giant cells showed immunoreactivity for CD68 and HAM 56 but were negative for CD163 and cytokeratins.
  • Giant cell tumors of the extrahepatic biliary tree are benign true histiocytic neoplasms that should be distinguished from the highly lethal anaplastic spindle and giant cell carcinomas with osteoclast-like giant cells by detailed cytologic analysis and immunohistochemical stains for CD163, CD68, HAM 56, and cytokeratins.
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Ducts, Extrahepatic / pathology. Giant Cell Tumors / pathology
  • [MeSH-minor] Adenocarcinoma / diagnosis. Carcinoma / diagnosis. Cholestasis, Extrahepatic / etiology. Cholestasis, Extrahepatic / pathology. Cholestasis, Extrahepatic / surgery. Diagnosis, Differential. Disease-Free Survival. Female. Humans. Male. Middle Aged. Osteoclasts / pathology

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Surg Pathol. 2008 Feb;32(2):335-7; author response 337 [18223338.001]
  • (PMID = 16625096.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Sciubba DM, Burdette EC, Cheng JJ, Pennant WA, Noggle JC, Petteys RJ, Alix C, Diederich CJ, Fichtinger G, Gokaslan ZL, Murphy KP: Percutaneous computed tomography fluoroscopy-guided conformal ultrasonic ablation of vertebral tumors in a rabbit tumor model. Laboratory investigation. J Neurosurg Spine; 2010 Dec;13(6):773-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Percutaneous computed tomography fluoroscopy-guided conformal ultrasonic ablation of vertebral tumors in a rabbit tumor model. Laboratory investigation.
  • OBJECT: Radiofrequency ablation (RFA) has proven to be effective for treatment of malignant and benign tumors in numerous anatomical sites outside the spine.
  • The major challenge of using RFA for spinal tumors is difficulty protecting the spinal cord and nerves from damage.
  • However, conforming ultrasound energy to match the exact anatomy of the tumor may provide successful ablation in such sensitive locations.
  • In a rabbit model of vertebral body tumor, the authors have successfully ablated tumors using an acoustic ablator placed percutaneously via computed tomography fluoroscopic (CTF) guidance.
  • At 21 days, a bone biopsy needle was placed into the geographical center of the lesion, down which an acoustic ablator was inserted.
  • Three multisensor thermocouple arrays were placed around the lesion to provide measurement of tissue temperature during ablation, at thermal doses ranging from 100 to 1,000,000 TEM (thermal equivalent minutes at 43°C), and tumor volumes were given a tumoricidal dose of acoustic energy.
  • Pathological specimens were obtained to determine the extent of tumor death and surrounding tissue damage.
  • Measured temperature distributions were used to reconstruct volumetric doses of energy delivered to tumor tissue, and such data were correlated with pathological findings.
  • The CTF guidance provided accurate placement of the acoustic ablator in all tumors, as corroborated through gross and microscopic histology.
  • Significant tumor death was noted in all specimens without collateral damage to nearby nerve tissue.
  • Tissue destruction just beyond the margin of the tumor was noted in some but not all specimens.
  • CONCLUSIONS: Using a rabbit intravertebral tumor model, the authors have successfully delivered tumoricidal doses of acoustic energy via a therapeutic ultrasound ablation probe placed percutaneously with CTF guidance.
  • The authors have thus established the first technical and preclinical feasibility study of controlled ultrasound ablation of spinal tumors in vivo.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21121752.001).
  • [ISSN] 1547-5646
  • [Journal-full-title] Journal of neurosurgery. Spine
  • [ISO-abbreviation] J Neurosurg Spine
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA112852-03; United States / NCI NIH HHS / CA / R44 CA112852; United States / NCI NIH HHS / CA / R44 CA112852-03
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Sponer P, Urban K, Urbanová E: [Scintigraphic detection of osteoblast activity after implantation of BAS-0 bioactive glass-ceramic material into long bone defects]. Acta Chir Orthop Traumatol Cech; 2006 Jun;73(3):176-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Scintigraphic detection of osteoblast activity after implantation of BAS-0 bioactive glass-ceramic material into long bone defects].
  • PURPOSE OF THE STUDY: The aim of the study was to demonstrate, by three-phase bone scintigraphy, radionuclide uptake at the site of defects in long bones filled with the non-resorbable bioactive glass-ceramic material BAS-0 at a long follow-up.
  • MATERIAL: Twenty patients, 14 men and 6 women, operated on between 1990 and 2000 for benign bone tumors or tumor-like lesions localized in the femur, tibia or humerus were comprised in the study.
  • The diagnoses based on histological examination included juvenile bone cysts in 11, aneurysmal bone cyst in five, non-ossifying fibroma in two, and fibrous dysplasia in two patients.
  • Three-phase bone scans were made and the healthy and the affected limbs in each patient were compared by means of an index.
  • On three-phase bone scans, radionuclide distribution on the flow phase and soft tissue phase was symmetrical in both limbs of all patients.
  • This changes local mechanical signals, which has a negative effect on the adjacent bone tissue.
  • Stress accumulating at the interface of a rigid implant and bone tissue may result in pain, and is detected by scintigraphy as an increased nucleotide uptake, particularly in diaphyseal grafts.
  • [MeSH-major] Bone Diseases / therapy. Bone Substitutes. Bone and Bones / radionuclide imaging. Ceramics. Osseointegration. Prostheses and Implants

  • MedlinePlus Health Information. consumer health - Bone Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16846563.001).
  • [ISSN] 0001-5415
  • [Journal-full-title] Acta chirurgiae orthopaedicae et traumatologiae Cechoslovaca
  • [ISO-abbreviation] Acta Chir Orthop Traumatol Cech
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / BAS O glass ceramic; 0 / Bone Substitutes
  •  go-up   go-down


20. Morales Alba NA: Posterior placement of an expandable cage for lumbar vertebral body replacement in oncologic surgery by posterior simple approach: technical note. Spine (Phila Pa 1976); 2008 Nov 1;33(23):E901-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Decompression techniques for vertebral body destruction by tumors and invasion of the spinal canal could need a second surgery for the resection of the tumor and stabilization of the anterior column, which could add morbidity for the patient.
  • METHODS: A 17-year-old woman with a benign fibrous histiocytoma in L5 with severe bone destruction, anterior and posterior underwent posterior decompression, vertebral body replacement at the same approach with an expandable cage and L4 S1 pedicle screw fixation in a single stage surgery.
  • This technique consist the resection of the tumor was performed under microscopic view and the vertebral body defect in L5 was resized with a high speed drill to allow the placement of the cage.
  • Then apedicular screw fixation was performed between L4 and S1, and fusion was completed with synthetic bone graft substitute (beta-tricalcium phosphate).
  • This technique could be used in surgery of vertebral body tumors of the lumbar spine, in a single surgical approach.
  • [MeSH-major] Histiocytoma, Benign Fibrous / surgery. Lumbar Vertebrae / surgery. Orthopedic Procedures / instrumentation. Reconstructive Surgical Procedures / instrumentation. Spinal Neoplasms / surgery
  • [MeSH-minor] Adolescent. Decompression, Surgical / methods. Female. Humans. Magnetic Resonance Imaging. Pain / diagnosis. Pain / etiology. Pain / surgery. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18978584.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Mohler DG, Chiu R, McCall DA, Avedian RS: Curettage and cryosurgery for low-grade cartilage tumors is associated with low recurrence and high function. Clin Orthop Relat Res; 2010 Oct;468(10):2765-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Curettage and cryosurgery for low-grade cartilage tumors is associated with low recurrence and high function.
  • BACKGROUND: Chondrosarcomas of bone traditionally have been treated by wide or radical excision, procedures that may result in considerable lifelong disability.
  • Grade 1 chondrosarcomas have little or no metastatic potential and are often difficult to distinguish from painful benign enchondromas.
  • Forty-one patients had tumors of the long bones.
  • Patients were followed a minimum of 18 months (average, 47.2. months; range, 18-134 months) for evidence of recurrence and for assessment of Musculoskeletal Tumor Society (MSTS) functional score.
  • RESULTS: Two of the 46 patients had recurrences in the original tumor site (4.3% recurrence rate), which subsequently were removed by wide excision, and both patients were confirmed to be disease-free 36 and 30 months, respectively, after the second surgery.
  • [MeSH-major] Bone Neoplasms / surgery. Chondroma / surgery. Chondrosarcoma / surgery. Cryosurgery. Curettage
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Recovery of Function. Retrospective Studies. Time Factors. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Orthop Relat Res. 1994 Oct;(307):189-99 [7924033.001]
  • [Cites] Clin Orthop Relat Res. 1993 Jan;(286):241-6 [8425352.001]
  • [Cites] Cancer. 1996 Apr 1;77(7):1292-7 [8608505.001]
  • [Cites] Eur J Surg Oncol. 1998 Apr;24(2):120-6 [9591027.001]
  • [Cites] Ann Surg Oncol. 1998 Jul-Aug;5(5):423-36 [9718172.001]
  • [Cites] J Bone Joint Surg Am. 1963 Oct;45:1450-8 [14069783.001]
  • [Cites] Lancet Oncol. 2005 Jan;6(1):25-34 [15629273.001]
  • [Cites] Clinics (Sao Paulo). 2005 Apr;60(2):121-6 [15880247.001]
  • [Cites] Clin Orthop Relat Res. 2006 Oct;451:201-7 [16788412.001]
  • [Cites] Clin Orthop Relat Res. 2007 Jun;459:146-9 [17452919.001]
  • [Cites] J Bone Joint Surg Am. 2007 Oct;89(10):2113-23 [17908885.001]
  • [Cites] Clin Orthop Relat Res. 2007 Oct;463:166-72 [17632422.001]
  • [Cites] J Surg Oncol. 2008 Nov 1;98(6):421-6 [18668642.001]
  • [Cites] Med Sci Monit. 2009 Mar;15(3):CS44-8 [19247248.001]
  • [Cites] Clin Orthop Relat Res. 2009 Aug;467(8):2105-11 [19142690.001]
  • [Cites] Eur J Surg Oncol. 2009 Dec;35(12):1343-7 [19570648.001]
  • [Cites] Clin Orthop Relat Res. 2010 Feb;468(2):581-9 [19727994.001]
  • [Cites] Clin Orthop Relat Res. 2010 Jul;468(7):1956-62 [20054673.001]
  • [Cites] Clin Orthop Relat Res. 1982 Mar;(163):231-4 [6950821.001]
  • [Cites] J Am Acad Orthop Surg. 2000 Sep-Oct;8(5):292-304 [11029557.001]
  • [Cites] Clin Orthop Relat Res. 2002 Apr;(397):106-13 [11953602.001]
  • [Cites] Cancer. 2003 Jun 1;97(11):2830-8 [12767097.001]
  • [Cites] Clin Orthop Relat Res. 1977 Jan-Feb;(122):147-56 [837601.001]
  • [Cites] J Bone Joint Surg Br. 1979 Nov;61-B(4):395-400 [500746.001]
  • [Cites] Clin Orthop Relat Res. 1980 Nov-Dec;(153):44-66 [7449231.001]
  • [Cites] Clin Orthop Relat Res. 1985 Dec;(201):214-37 [4064409.001]
  • [Cites] Acta Orthop Scand. 1995 Jun;66(3):283-8 [7604716.001]
  • (PMID = 20574801.001).
  • [ISSN] 1528-1132
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3049634
  •  go-up   go-down


22. Miaśkiewicz B, Lukomski M, Starska K, Józefowicz-Korczyńska M: [Ocular and orbital symptoms in benign sinonasal neopasmas]. Pol Merkur Lekarski; 2006 Feb;20(116):184-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ocular and orbital symptoms in benign sinonasal neopasmas].
  • Osteoma (0.01-0.4%) and inverted papilloma (0.5-4%) are the most common benign tumours of the nose and paranasal sinuses, whereas heamangioma occurs very rare.
  • AIM OF THE STUDY: Analysis of symtoms, diagnostic procedures and treatment options in 10 patients with diagnosed orbital and ocular complications of benign tumours of the nose and paranasal sinuses.
  • In 8 cases there were signs of bone destruction in CT, what was intraoperatively confirmed in 4 cases.
  • RESULTS: Nine of the patients were operated: 4--lateral rhinotomies, 2--Denker's operations, 2--operations of sinus frontalis and/or ethmoidalis by external approach and in 1 case resection of maxilllary sinus's tumor were performed.
  • The rest of patients stay without recurrences of tumor.
  • CONCLUSION: Orbital and ocular symptoms in benign tumors of nose and paranasal sinuses do not always correlate with radiologic and intraoperative findings.

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Headache.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16708636.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


23. Mao HW, Liu WL, Zhou JF, Sun HY, Xu HZ, Luo XH: [Expression of plk-1 gene in acute leukemia patients and its significance]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Oct;14(5):876-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To investigate expression of plk-1 gene and PLK-1 protein in acute leukemia patients and its clinical significance, and to observe the distribution of PLk-1 protein in acute leukemin cells, the mononuclear cells were separated from the bone marrow or peripheral blood of acute leukemia patients, bone marrow benign proliferation individuals and normal individuals.
  • The result showed that the expressions of plk-1 gene and PLK-1 protein in mononuclear cells of acute leukemia patients were much higher than that of bone marrow benign proliferation individuals and normal individuals.
  • Fluorescent inverted microscopy revealed that PLK-1 was highly concentrated in cytoplasm of acute leukemia cells during interphase of mitosis, and it was found that PLK-1 was mainly distributed between sister chromatid during the mitosis in mononuclear cells of acute leukemia patients, but the expressions of plk-1 gene and PLK-1 protein almost were not observed in cells of benign proliferative bone marrow and normal bone marrow.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17096880.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Proto-Oncogene Proteins; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / polo-like kinase 1
  •  go-up   go-down


24. Fu K, Meng ZB, Li J, Li HC: [Repairing the defect of benign bone tumor with the coralline hydroxyapatite]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2008 May;33(5):421-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Repairing the defect of benign bone tumor with the coralline hydroxyapatite].
  • OBJECTIVE: To observe the clinical effect of repairing bone defectin post-operation benign tumor with coralline hydroxyapatite(CHAP).
  • The CHAP was implanted into the lesion after bone tumor curettage to 25 patients.
  • The sizes of bone defect ranged from 0.8 cm x 0.5 cm x 0.5 cm to 10 cm x 3.5 cm x 2 cm.
  • X-ray showed that there was osteogenesis at the cortical bone 1 month post-operation.
  • There is corresponding synchronization between bone formation with CHAP biodegradation.
  • The CHAP is an excellent bone defect repairing material.
  • [MeSH-major] Bone Neoplasms / surgery. Ceramics. Giant Cell Tumor of Bone / surgery. Hydroxyapatites. Prostheses and Implants
  • [MeSH-minor] Adolescent. Adult. Aged. Bone Cysts / surgery. Bone Regeneration. Bone Substitutes. Child. Female. Femur / surgery. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18544846.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Bone Substitutes; 0 / Hydroxyapatites; 0 / coralline hydroxyapatite
  •  go-up   go-down


25. Akahane T, Shimizu T, Isobe K, Yoshimura Y, Kato H: Serum soluble interleukin-2 receptor levels in patients with malignant lymphoma of bone. J Orthop Sci; 2009 May;14(3):248-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum soluble interleukin-2 receptor levels in patients with malignant lymphoma of bone.
  • BACKGROUND: The reliability of selected serum markers and radiological features for distinguishing malignant lymphoma of the bone from other osteolytic bone lesions was examined in an effort to improve the differential diagnosis.
  • METHODS: A total of 23 patients with histologically verified malignant lymphoma of the bone, 57 patients with other osteolytic malignancies (35 males, 22 females; mean age 62.8 years, range 13-89 years), and 13 patients with benign bone lesions that resemble malignant tumor radiographically (6 men, 7 women; mean age 48.1 years, range 20-73 years) were retrospectively reviewed.
  • CONCLUSIONS: The serum sIL-2R level can be a valuable marker for diagnosing malignant lymphoma of the bone.
  • [MeSH-major] Biomarkers, Tumor / blood. Bone Neoplasms / blood. Lymphoma / blood. Receptors, Interleukin-2 / blood

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19499289.001).
  • [ISSN] 1436-2023
  • [Journal-full-title] Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association
  • [ISO-abbreviation] J Orthop Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Interleukin-2
  •  go-up   go-down


26. Bassiony AA, Abdelrahman M, Abdelhady A, Assal MK: Resection arthrodesis for the management of aggressive giant cell tumor of the distal femur. Indian J Orthop; 2009 Jan;43(1):67-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resection arthrodesis for the management of aggressive giant cell tumor of the distal femur.
  • BACKGROUND: Giant cell tumors (GCTs) of bone are aggressive benign tumors.
  • Wide resection is reserved for a small subset of patients with biologically more aggressive, recurrent, and extensive tumors.
  • Wide resection and mobile joint reconstruction are preferable for treating tumors around the knee.
  • MATERIALS AND METHODS: Eight patients with mean age of 37.25 years (range 30-45 years) with Campanacci Grade III (Enneking stage III) giant cell tumors at the distal femur were treated with wide resection and arthrodesis using dual free fibular graft and locked intramedullary nail from January 2003 to January 2008.
  • The functional evaluation was done using the standard system of musculoskeletal tumor society with its modification developed by Enneking et al.
  • Graft union was achieved in all cases in a duration mean of 14.5 months (range 12-20 months).One case required secondary bone graft due to delayed union, and one case had superficial wound infection which healed on systemic antibiotics.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bone Joint Surg Br. 1996 Mar;78(2):264-9 [8666639.001]
  • [Cites] Clin Orthop Relat Res. 1993 Jan;(286):241-6 [8425352.001]
  • [Cites] J Bone Joint Surg Am. 1998 May;80(5):636-47 [9611024.001]
  • [Cites] J Bone Joint Surg Am. 1999 Jun;81(6):811-20 [10391546.001]
  • [Cites] Arch Orthop Trauma Surg. 2000;120(3-4):215-8 [10738888.001]
  • [Cites] Clin Orthop Relat Res. 2001 Jul;(388):167-77 [11451116.001]
  • [Cites] J Bone Joint Surg Br. 2004 Jan;86(1):5-12 [14765857.001]
  • [Cites] Ann Acad Med Singapore. 2005 Apr;34(3):235-7 [15902343.001]
  • [Cites] J Surg Oncol. 2005 Oct 1;92(1):46-51 [16180228.001]
  • [Cites] Orthop Clin North Am. 2006 Jan;37(1):35-51 [16311110.001]
  • [Cites] Am J Clin Oncol. 2006 Feb;29(1):96-9 [16462511.001]
  • [Cites] J Bone Joint Surg Br. 2006 Dec;88(12):1642-6 [17159179.001]
  • [Cites] Indian J Orthop. 2007 Apr;41(2):124-8 [21139764.001]
  • [Cites] Indian J Orthop. 2007 Apr;41(2):129-33 [21139765.001]
  • [Cites] J Bone Joint Surg Am. 1990 Dec;72(10):1477-85 [2254355.001]
  • [Cites] J Bone Joint Surg Am. 1990 Apr;72(4):486-94 [2324134.001]
  • [Cites] J Orthop Res. 1989;7(4):463-7 [2738764.001]
  • [Cites] Clin Orthop Relat Res. 1987 Aug;(221):188-201 [3301143.001]
  • [Cites] Arch Orthop Trauma Surg. 1986;105(2):67-72 [3718192.001]
  • [Cites] J Bone Joint Surg Am. 1986 Sep;68(7):1073-9 [3745247.001]
  • [Cites] J Bone Joint Surg Am. 1987 Jan;69(1):106-14 [3805057.001]
  • [Cites] Cancer. 1970 May;25(5):1061-70 [4910256.001]
  • [Cites] J Bone Joint Surg Br. 1994 Mar;76(2):178-86 [8113272.001]
  • [Cites] J Bone Joint Surg Br. 1997 Jan;79(1):36-42 [9020442.001]
  • (PMID = 19753183.001).
  • [ISSN] 0019-5413
  • [Journal-full-title] Indian journal of orthopaedics
  • [ISO-abbreviation] Indian J Orthop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2739496
  • [Keywords] NOTNLM ; Giant cell tumor / intra medullary nail / resection arthrodesis
  •  go-up   go-down


27. Aghajanzadeh M, Alavy A, Taskindost M, Pourrasouly Z, Aghajanzadeh G, Massahnia S: Results of chest wall resection and reconstruction in 162 patients with benign and malignant chest wall disease. J Thorac Dis; 2010 Jun;2(2):81-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of chest wall resection and reconstruction in 162 patients with benign and malignant chest wall disease.
  • The most common indications for surgery were primary chest wall tumors.
  • CONCLUSIONS: Chest wall resection and reconstruction with Bone cement sandwich with mesh can be performed as a safe and effective surgical procedure for major chest wall defects and respiratory failure is lower in prosthetic reconstruction patients than previously reported (6).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22263024.001).
  • [ISSN] 2077-6624
  • [Journal-full-title] Journal of thoracic disease
  • [ISO-abbreviation] J Thorac Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC3256447
  • [Keywords] NOTNLM ; chest wall disease / chest wall resection / chest wall tumor
  •  go-up   go-down


28. Tiet TD, Hopyan S, Nadesan P, Gokgoz N, Poon R, Lin AC, Yan T, Andrulis IL, Alman BA, Wunder JS: Constitutive hedgehog signaling in chondrosarcoma up-regulates tumor cell proliferation. Am J Pathol; 2006 Jan;168(1):321-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Constitutive hedgehog signaling in chondrosarcoma up-regulates tumor cell proliferation.
  • Chondrosarcoma is a malignant cartilage tumor that may arise from benign precursor lesions, such as enchondromas.
  • Chondrosarcoma xenografts from 12 different human tumors were established in NOD-SCID mice.
  • Treatment with triparanol, an inhibitor of Hedgehog signaling, resulted in a 60% decrease in tumor volume, a 30% decrease in cellularity, and a 20% reduction in proliferation rate.
  • These results show that Hedgehog signaling is active in chondrosarcoma and benign cartilage tumors and regulates tumor cell proliferation.
  • Our data raise the intriguing possibility that Hedgehog blockade could serve as an effective treatment for chondrosarcoma, a tumor for which there are currently no universally effective nonsurgical management options.
  • [MeSH-major] Bone Neoplasms / metabolism. Cell Proliferation. Chondrosarcoma / metabolism. Parathyroid Hormone-Related Protein / metabolism. Signal Transduction / physiology. Trans-Activators / metabolism

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Endocrinol. 1996 Sep;150(3):359-68 [8882154.001]
  • [Cites] Cell. 1996 Nov 15;87(4):661-73 [8929535.001]
  • [Cites] J Endocrinol. 1997 Sep;154 Suppl:S39-45 [9379136.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13689-94 [9391087.001]
  • [Cites] Science. 1998 Jun 5;280(5369):1603-7 [9616123.001]
  • [Cites] Oncogene. 1999 Jan 21;18(3):783-8 [9989829.001]
  • [Cites] Arch Biochem Biophys. 1959 Nov;85:250-63 [13801562.001]
  • [Cites] J Orthop Res. 1999 Sep;17(5):633-8 [10569470.001]
  • [Cites] Curr Biol. 1999 Nov 18;9(22):1319-22 [10574767.001]
  • [Cites] Dev Dyn. 2000 Jul;218(3):452-64 [10878610.001]
  • [Cites] Nature. 2000 Aug 31;406(6799):944-5 [10984033.001]
  • [Cites] Lab Invest. 2000 Dec;80(12):1925-34 [11140704.001]
  • [Cites] Endocrinology. 2001 Mar;142(3):1260-8 [11181543.001]
  • [Cites] J Clin Invest. 2001 Feb;107(3):295-304 [11160153.001]
  • [Cites] Oncogene. 2001 Jan 25;20(4):451-60 [11313976.001]
  • [Cites] Nature. 2001 May 17;411(6835):349-54 [11357142.001]
  • [Cites] Mech Dev. 2001 Aug;106(1-2):107-17 [11472839.001]
  • [Cites] Mol Biol Cell. 2001 Dec;12(12):3852-63 [11739785.001]
  • [Cites] Development. 2001 Dec;128(24):5099-108 [11748145.001]
  • [Cites] J Bone Joint Surg Br. 2002 Jan;84(1):93-9 [11837841.001]
  • [Cites] Nat Genet. 2002 Mar;30(3):306-10 [11850620.001]
  • [Cites] Pathology. 2002 Apr;34(2):133-7 [12009094.001]
  • [Cites] Development. 2002 Jun;129(12):2977-86 [12050144.001]
  • [Cites] J Cell Sci. 2002 Jul 15;115(Pt 14):3015-25 [12082161.001]
  • [Cites] Science. 2002 Aug 30;297(5586):1559-61 [12202832.001]
  • [Cites] Clin Orthop Relat Res. 2002 Oct;(403):198-204 [12360027.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4616-21 [12679522.001]
  • [Cites] Hum Mol Genet. 2003 May 15;12(10):1187-98 [12719383.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):846-51 [14520411.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):851-6 [14520413.001]
  • [Cites] J Pathol. 2004 Jan;202(1):113-20 [14694528.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6071-4 [15342389.001]
  • [Cites] Cancer Cell. 2004 Sep;6(3):229-40 [15380514.001]
  • [Cites] Nature. 2004 Oct 7;431(7009):707-12 [15361885.001]
  • [Cites] J Bone Joint Surg Am. 1987 Feb;69(2):269-74 [3805090.001]
  • [Cites] Am J Vet Res. 1993 Jul;54(7):1116-21 [8368608.001]
  • [Cites] J Cell Biol. 1994 Sep;126(6):1611-23 [8089190.001]
  • [Cites] Dev Biol. 1996 Apr 10;175(1):166-76 [8608863.001]
  • [Cites] Science. 1996 Aug 2;273(5275):613-22 [8662546.001]
  • [Cites] Science. 1996 Aug 2;273(5275):663-6 [8662561.001]
  • [Cites] Arch Biochem Biophys. 1959 Nov;85:245-9 [13801564.001]
  • [Cites] Hum Mutat. 2004 Dec;24(6):466-73 [15523647.001]
  • [Cites] J Pathol. 2005 Mar;205(4):476-82 [15685701.001]
  • [Cites] Endocrinology. 1996 Nov;137(11):5055-67 [8895380.001]
  • (PMID = 16400033.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gli protein; 0 / Hedgehog Proteins; 0 / Hypolipidemic Agents; 0 / Oncogene Proteins; 0 / Parathyroid Hormone-Related Protein; 0 / Receptors, Cell Surface; 0 / Trans-Activators; 0 / Transcription Factors; 0 / patched receptors; 63S8C3RXGS / Triparanol
  • [Other-IDs] NLM/ PMC1592680
  •  go-up   go-down


29. Uysal A, Sungur N, Koçer U, Cöloğlu H, Oruç M, Yalta T: Neuromuscular hamartoma of the occipital nerve: clinical report. J Craniofac Surg; 2005 Jul;16(4):740-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neuromuscular hamartoma is a rare benign tumor consisted of well-differentiated striated muscle fibers within mature neural elements.
  • Though most cases are composed of solitary masses associated with major peripheral nerves, multiple tumors or subcutaneous tumors without any association with peripheral nerves have also been reported.
  • There have been no reports of this tumor in association with the occipital nerve.
  • [MeSH-minor] Child. Female. Humans. Muscle Fibers, Skeletal. Nerve Fibers. Neuromuscular Diseases / pathology. Neuromuscular Diseases / surgery. Occipital Bone. Scalp / innervation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16077331.001).
  • [ISSN] 1049-2275
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Moh EN, Aguehoundé C, Aké YL, Kéita A, Kotaix L: [Reconstruction using non-vascularized fibula of an aneurysmal bone cyst of the humerus in a child]. Mali Med; 2010;25(1):64-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Reconstruction using non-vascularized fibula of an aneurysmal bone cyst of the humerus in a child].
  • [Transliterated title] Reconstruction par Fibula non Vascularisee d'un Kyste Osseux Anevrysmal de L'Humerus Chez L'Enfant.
  • Aneurysmal bone cyst is a pseudotumoral bone dystrophy which accounts for 1.5 to 4% of benign bone tumours.
  • [MeSH-major] Bone Cysts, Aneurysmal / surgery. Fibula / transplantation. Humerus / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21436008.001).
  • [ISSN] 1993-0836
  • [Journal-full-title] Le Mali médical
  • [ISO-abbreviation] Mali Med
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Mali
  •  go-up   go-down


31. Malek F, Krueger P, Hatmi ZN, Malayeri AA, Faezipour H, O'Donnell RJ: Local control of long bone giant cell tumour using curettage, burring and bone grafting without adjuvant therapy. Int Orthop; 2006 Dec;30(6):495-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local control of long bone giant cell tumour using curettage, burring and bone grafting without adjuvant therapy.
  • Giant cell tumour (GCT) is a benign, but aggressive, primary tumour of the bone.
  • Many surgical techniques have been employed in the treatment of this tumour.
  • In addition to curettage, various adjuvant procedures and packing materials have been advocated in order to control and reconstruct long bone defects secondary to this neoplasm.
  • We report our experience with 40 long bone GCT patients treated with curettage, burring, bone grafting and no adjuvants between 1997 and 2002.
  • The risk of local recurrence in this study is acceptable (within the range that has been historically reported for curettage and bone grafting).
  • [MeSH-major] Bone Neoplasms / surgery. Bone Transplantation / methods. Giant Cell Tumor of Bone / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Cohort Studies. Developing Countries. Female. Humans. Iran. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Grafts.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Orthop Relat Res. 2002 Apr;(397):259-70 [11953617.001]
  • [Cites] Clin Orthop Relat Res. 2002 Apr;(397):248-58 [11953616.001]
  • [Cites] J Bone Joint Surg Am. 1970 Jun;52(4):619-64 [5479455.001]
  • [Cites] Recent Results Cancer Res. 1976;(54):257-61 [1013500.001]
  • [Cites] J Bone Joint Surg Am. 1980;62(4):652-6 [7380862.001]
  • [Cites] J Bone Joint Surg Am. 1982 Jun;64(5):755-61 [7045129.001]
  • [Cites] Clin Orthop Relat Res. 1986 Mar;(204):9-24 [3456859.001]
  • [Cites] J Bone Joint Surg Am. 1987 Jan;69(1):106-14 [3805057.001]
  • [Cites] Chir Organi Mov. 1990;75(1 Suppl):206 [2249534.001]
  • [Cites] J Bone Joint Surg Am. 1993 Nov;75(11):1648-55 [8245057.001]
  • [Cites] J Bone Joint Surg Am. 1994 Dec;76(12):1827-33 [7989388.001]
  • [Cites] Clin Orthop Relat Res. 1995 Dec;(321):245-50 [7497676.001]
  • [Cites] Bull Hosp Jt Dis. 1998;57(1):6-10 [9553696.001]
  • [Cites] Pathol Int. 1998 Sep;48(9):723-9 [9778111.001]
  • [Cites] J Bone Joint Surg Am. 1999 Jun;81(6):811-20 [10391546.001]
  • [Cites] Bull Hosp Jt Dis. 1999;58(2):98-104 [10509202.001]
  • [Cites] Clin Orthop Relat Res. 2005 Jun;(435):211-8 [15930941.001]
  • [Cites] Clin Orthop Relat Res. 2005 Oct;439:144-50 [16205153.001]
  • [Cites] Clin Orthop Relat Res. 2002 Jul;(400):201-10 [12072763.001]
  • (PMID = 16896875.001).
  • [ISSN] 0341-2695
  • [Journal-full-title] International orthopaedics
  • [ISO-abbreviation] Int Orthop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC3172751
  •  go-up   go-down


32. Vincourt JB, Etienne S, Cottet J, Delaunay C, Malanda CB, Lionneton F, Sirveaux F, Netter P, Plénat F, Mainard D, Vignaud JM, Magdalou J: C-propeptides of procollagens I alpha 1 and II that differentially accumulate in enchondromas versus chondrosarcomas regulate tumor cell survival and migration. Cancer Res; 2010 Jun 1;70(11):4739-48
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] C-propeptides of procollagens I alpha 1 and II that differentially accumulate in enchondromas versus chondrosarcomas regulate tumor cell survival and migration.
  • Chondrogenic tumors that exhibit benign or malignant behaviors synthesize variable amounts of cartilage-like extracellular matrix.
  • To define the regulators of these phenotypes, we performed a proteomic comparison of multiple human chondrogenic tumors, which revealed differential accumulation of the C-propeptides of procollagens Ialpha1 and II (PC1CP and PC2CP) in malignant versus benign tumors, respectively.
  • Expression patterns of PC1CP correlated with levels of tumor vascularization, whereas expression patterns of PC2CP suggested its susceptibility to immobilization within the extracellular matrix.
  • Our findings suggest that PC1CP favors angiogenesis and tumor progression, but that PC2CP acts in a more complex manner, exerting antitumor and antiangiogenic properties through apoptosis induction when immobilized, but progression and metastasis when soluble.
  • In summary, the relative levels of PC1CP and PC2CP and their interactions within the extracellular matrix contribute to tumor progression, angiogenesis, and metastasis in chondrogenic tumors.
  • [MeSH-major] Bone Neoplasms / metabolism. Chondroma / metabolism. Chondrosarcoma / metabolism. Collagen Type I / metabolism. Collagen Type II / metabolism

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Addgene Non-profit plasmid repository. clones/clone libraries - Get Article's Plasmids - Addgene (subscription/membership/fee required).
  • The Lens. Cited by Patents in .
  • eagle-i research resources. PMID 20460531 (Special Collections) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 AACR.
  • [ErratumIn] Cancer Res. 2010 Jul 1;70(13):5639. Malanda, Bantsimba [corrected to Malanda, Claudie Bantsimba]
  • (PMID = 20460531.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD29; 0 / COL2A1 protein, human; 0 / Collagen Type I; 0 / Collagen Type II; 0 / Disulfides; 0 / Protein Precursors; 0 / Recombinant Proteins; 0 / collagen type I, alpha 1 chain
  •  go-up   go-down


33. Patrício JP, Oliveira P, Fernandes H, Oliveira A, Faria MT, Pérez MB, Pereira J: [Osteoid osteoma]. Acta Med Port; 2009 Sep-Oct;22(5):613-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Osteoid osteoma is the third most common benign bone tumor.
  • The three phase bone scintigraphy revealed a focal uptake in the mid shaft of the left femur, strongly suggestive of osteoid osteoma.
  • This case shows the significant role of bone scintigraphy in the diagnosis of an osteoma osteoid with atipical presentation.
  • [MeSH-major] Femoral Neoplasms / diagnosis. Osteoma, Osteoid / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19944046.001).
  • [ISSN] 1646-0758
  • [Journal-full-title] Acta médica portuguesa
  • [ISO-abbreviation] Acta Med Port
  • [Language] por
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Portugal
  •  go-up   go-down


34. Bahnassy M, Abdul-Khalik H: Soft tissue chondroma: a case report and literature review. Oman Med J; 2009 Oct;24(4):296-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Extra skeletal soft tissue chondroma is a very rare, slow progressing, benign tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22216384.001).
  • [ISSN] 1999-768X
  • [Journal-full-title] Oman medical journal
  • [ISO-abbreviation] Oman Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Oman
  • [Other-IDs] NLM/ PMC3243868
  •  go-up   go-down


35. Saglik Y, Altay M, Unal VS, Basarir K, Yildiz Y: Manifestations and management of osteochondromas: a retrospective analysis of 382 patients. Acta Orthop Belg; 2006 Dec;72(6):748-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Osteochondromas represent the most common primary bone tumours; they reportedly represent 20-50% of all benign bone tumours and 10-15% of all bone tumours.
  • [MeSH-major] Bone Neoplasms / diagnosis. Bone Neoplasms / surgery. Osteochondroma / diagnosis. Osteochondroma / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Exostoses, Multiple Hereditary / complications. Exostoses, Multiple Hereditary / diagnosis. Exostoses, Multiple Hereditary / surgery. Female. Humans. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17260614.001).
  • [ISSN] 0001-6462
  • [Journal-full-title] Acta orthopaedica Belgica
  • [ISO-abbreviation] Acta Orthop Belg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


36. Cleeman E, Auerbach JD, Springfield DS: Tumors of the shoulder girdle: a review of 194 cases. J Shoulder Elbow Surg; 2005 Sep-Oct;14(5):460-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumors of the shoulder girdle: a review of 194 cases.
  • The upper extremity is the third most common site of primary bone and soft-tissue tumors.
  • The purpose of this study was to determine the types and prevalence of bone and soft-tissue tumors that occur in the shoulder girdle and to identify physical findings that may be indicative of malignancy.
  • Benign tumors (n = 139) were more common than malignant tumors (n = 55).
  • Malignant tumors occurred in an older population (P < .0007).
  • Tenderness and tumor location in the scapula were also found to be risk factors for malignancy (P = .0002 and P = .0001, respectively).

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16194735.001).
  • [ISSN] 1058-2746
  • [Journal-full-title] Journal of shoulder and elbow surgery
  • [ISO-abbreviation] J Shoulder Elbow Surg
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Morbidi M, Ventura A, Della Rocca C: Arthroscopic assisted resection of juxta-articular osteoid osteoma. J Foot Ankle Surg; 2007 Nov-Dec;46(6):470-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Osteoid osteoma is a benign tumor of bone.
  • A juxta-articular case of osteoid osteoma involving the distal epiphysis of the tibia misdiagnosed by magnetic resonance imaging and correctly addressed by computed tomography scan and bone scans is presented.
  • In the present case, because the location of the disease was juxta-articular, arthroscopy was used to remove the tumor.
  • [MeSH-major] Ankle Joint / surgery. Arthroscopy. Bone Neoplasms / surgery. Joint Diseases / surgery. Osteoma, Osteoid / surgery. Tibia / surgery
  • [MeSH-minor] Adult. Chondromatosis, Synovial / diagnosis. Diagnosis, Differential. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Joint Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17980845.001).
  • [ISSN] 1067-2516
  • [Journal-full-title] The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons
  • [ISO-abbreviation] J Foot Ankle Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. George B, Archilli M, Cornelius JF: Bone tumors at the cranio-cervical junction. Surgical management and results from a series of 41 cases. Acta Neurochir (Wien); 2006 Jul;148(7):741-9; discussion 749
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone tumors at the cranio-cervical junction. Surgical management and results from a series of 41 cases.
  • BACKGROUND: Bone tumors located at the cranio-cervical junction (CCJ)are rare.
  • Tumoral involvement of the neighbouring structures including bone, nerves and vertebral artery and the dynamic aspects of the bone structures raise technical difficulties in the surgical approach.
  • METHODS: Forty-one patients presenting a bone tumor (26 benign and 15 malignant tumors), excluding chordomas, located at the CCJ (including lower third of the clivus, C1 and C2) were observed over 20 years from 1981 to 2001.
  • Imaging work-up included CT scanner with bone windows sequences and reconstruction in the coronal and sagittal plane; since 1984 most of the patients (N=35) underwent a MRI and angioMR scanning.
  • Vertebral angiography was rarely performed (N=9) and mostly when the diagnosis was doubtful.
  • In some cases the diagnosis was clear but in others, imaging studies showed destructive lesions suggesting a malignancy, which sometimes required a biopsy (N=4).
  • A complementary stabilization procedure was necessary in 18 cases using either bone grafting during the same procedure and through the same approach (N=5) or a craniocervical plating and bone grafting (N=13).
  • No recurrence in the group of benign tumors was seen during an average follow-up of 6 years (from 2 to 11 years).
  • CONCLUSIONS: Various types of bone tumors may be found at the CCJ.
  • Confusion between benign and malignant tumor or pseudo tumors must be avoided, sometimes requiring a biopsy.
  • [MeSH-major] Axis, Cervical Vertebra / surgery. Bone Neoplasms / surgery. Cervical Atlas / surgery. Neurosurgical Procedures / methods. Occipital Bone / surgery. Skull Base Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Cerebral Angiography. Child. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neck Pain / etiology. Neck Pain / physiopathology. Neck Pain / surgery. Neoplasm Metastasis / pathology. Neoplasm Metastasis / radiography. Neoplasm Recurrence, Local / prevention & control. Neoplasm Recurrence, Local / surgery. Postoperative Complications / etiology. Postoperative Complications / physiopathology. Retrospective Studies. Spinal Fusion. Tomography, X-Ray Computed. Treatment Outcome. Vertebral Artery / anatomy & histology. Vertebral Artery / pathology. Vertebral Artery / surgery

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16708168.001).
  • [ISSN] 0001-6268
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


39. Hagspiel KD: Manifestation of Hodgkin's lymphoma in an adrenal myelolipoma. Eur Radiol; 2005 Aug;15(8):1757-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adrenal myelolipomas are benign tumors histologically consisting of fat and bone marrow.
  • This collision tumor constellation has not been reported previously.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Hodgkin Disease / diagnosis. Myelolipoma / diagnosis. Neoplasms, Multiple Primary / diagnosis

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Radiol. 2002 Nov;57(11):1034-7 [12409116.001]
  • [Cites] AJR Am J Roentgenol. 1988 Nov;151(5):961-4 [3051964.001]
  • [Cites] Acta Cytol. 1984 May-Jun;28(3):269-82 [6587703.001]
  • [Cites] Arch Pathol Lab Med. 1981 Oct;105(10):532-5 [6895165.001]
  • [Cites] Surgery. 1973 May;73(5):665-70 [4697085.001]
  • [Cites] Abdom Imaging. 1994 Mar-Apr;19(2):165-7 [8199553.001]
  • [Cites] J Heart Lung Transplant. 1993 Nov-Dec;12(6 Pt 2):S328-36 [8312352.001]
  • [Cites] J Comput Assist Tomogr. 1978 Jan;2(1):11-5 [670463.001]
  • [Cites] Acta Cytol. 1991 May-Jun;35(3):353-6 [2042437.001]
  • [Cites] J Comput Assist Tomogr. 1991 Jan-Feb;15(1):111-4 [1987178.001]
  • (PMID = 15503042.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


40. Liu H, Sun J, Wang Y, Yang X, Zhu E: [Repairing bone defects of benign bone neoplasm by grafting of bioactive glass combined with autologous bone marrow]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2008 Nov;22(11):1349-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Repairing bone defects of benign bone neoplasm by grafting of bioactive glass combined with autologous bone marrow].
  • OBJECTIVE: To investigate the clinical application of grafting with bioactive glass (BG) and autologous bone marrow for defect after resection and curettage of benign bone neoplasm.
  • METHODS: From January 2004 to May 2007, 34 patients with bone defects were repaired.
  • There were 14 cases of simple bone cysts, 6 cases of fibrous dysplasia, 3 cases of osteoid osteoma, 4 cases of non-ossifying fibroma, 2 cases of enchondroma and 3 cases of giant cell tumor of bone.
  • Tumor sizes varied from 2.0 cm x 1.5 cm x 1.0 cm to 9.0 cm x 3.0 cm x 2.5 cm.
  • Benign bone neoplasm was removed thoroughly with a curet or osteotome, bone defects ranged from 3.0 cm x 2.0 cm x 1.5 cm to 11.0 cm x 3.5 cm x 3.0 cm, which was closed-up with the mixtures of BG and autogenous red bone marrow.
  • The postoperative systemic and local reactions were observed, and the regular X-ray examinations were performed to observe the bone healing.
  • At averaged 16 weeks after operation, patients with bone tumor in lower limbs resumed walking independently and those with bone tumor in upper limbs resumed holding object.
  • There was no tumor recurrence during follow-up.
  • Radiographically, the interface between the implanted bone and host bone became fuzzy 1 month after implantation.
  • Two months after operation, the BG was absorbed gradually, new bone formation could be seen in the defects.
  • Four months after operation, implanted bone and host bone merged together, bone density increased.
  • Six to ten months after operation, the majority of the implanted BG was absorbed and substituted for new bone, bone remodeling was established.
  • CONCLUSION: BG may boast both bone conductive and bone inductive activities.
  • The combined grafting with BG and autologous bone marrow appears to be minimally invasive treatment to repair bone defects of benign bone neoplasm, with rare complications and no significant reverse reaction, and could repair bone defects completely.
  • [MeSH-major] Bone Marrow Transplantation. Bone Substitutes. Postoperative Complications / surgery. Reconstructive Surgical Procedures / methods
  • [MeSH-minor] Adolescent. Adult. Bone Neoplasms / surgery. Bone and Bones / pathology. Child. Female. Follow-Up Studies. Glass. Humans. Male. Middle Aged. Transplantation, Autologous

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19068605.001).
  • [ISSN] 1002-1892
  • [Journal-full-title] Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery
  • [ISO-abbreviation] Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Bone Substitutes
  •  go-up   go-down


41. Arpino L, Gragnaniello C, Nina P, Franco A: Limited approach to a thoracic spine osteoblastoma. J Neurosurg Sci; 2008 Dec;52(4):123-5; discussion 125
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Osteoblastoma (OB) is a rare primary benign bone tumor.
  • The peak incidence of this neoplasm is in the first two decades of life.
  • It is important to differentiate OB from osteoid osteoma, a very similar bone tumor.
  • OB is rare benign bone neoplasm that generally affect the posterior elements of the spine.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18981987.001).
  • [ISSN] 0390-5616
  • [Journal-full-title] Journal of neurosurgical sciences
  • [ISO-abbreviation] J Neurosurg Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


42. Engels K, Oeschger S, Hansmann ML, Hillebrand M, Kriener S: Bone marrow trephines containing lymphoid aggregates from patients with rheumatoid and other autoimmune disorders frequently show clonal B-cell infiltrates. Hum Pathol; 2007 Sep;38(9):1402-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone marrow trephines containing lymphoid aggregates from patients with rheumatoid and other autoimmune disorders frequently show clonal B-cell infiltrates.
  • In bone marrow trephines, morphological and immunohistochemical criteria may not be sufficient to discriminate reactive from malignant lymphoid infiltrates.
  • The aim of this study was to determine whether the detection of clonal immunoglobulin heavy chain (IGH) gene rearrangements is a reliable and specific marker for malignant B-cell clones in bone marrow biopsies.
  • Bone marrow trephines with infiltration by different types of low-grade B-cell non-Hodgkin lymphoma (n = 32), reactive lymphoid hyperplasia (n = 18), and reactive lymphoid aggregates (n = 15), including 5 patients with rheumatoid or other autoimmune disorders, were analyzed by morphology, immunohistochemistry, IGH gene rearrangement (polymerase chain reaction), and DNA sequence analysis in selected cases.
  • Four of the patients with B-cell clonality had an autoimmune disorder.
  • Thus, the molecular detection of a clonal rearrangement of the IGH gene may support the diagnosis of a malignant lymphoma infiltrating the bone marrow.
  • However, morphologically and immunohistochemically benign lymphoid aggregates might also harbor B-cell clones especially in patients with autoimmune disorders.
  • Therefore, the detection of clonality has to be interpreted with utmost care and does not qualify for the unequivocal diagnosis of a malignant B-cell lymphoma.
  • [MeSH-major] Arthritis, Rheumatoid / pathology. Autoimmune Diseases / pathology. B-Lymphocytes / pathology. Bone Marrow / pathology. Gene Rearrangement. Immunoglobulin Heavy Chains / genetics. Lymphoid Tissue / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / genetics. Bone Marrow Examination. Clone Cells. Female. Humans. Hyperplasia / genetics. Immunohistochemistry. Lymphoma, B-Cell / pathology. Lymphoma, Non-Hodgkin / pathology. Male. Middle Aged. Polymerase Chain Reaction. Sequence Analysis, DNA

  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17560629.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


43. Zahid M, Asif N, Sabir AB, Siddiqui YS, Julfiqar M: Metachronous multicentric giant cell tumour of the upper extremity in a skeletally immature girl : A rare presentation. Acta Orthop Belg; 2010 Oct;76(5):694-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metachronous multicentric giant cell tumour of the upper extremity in a skeletally immature girl : A rare presentation.
  • Giant Cell tumour (GCT) or Osteoclastoma is a benign locally aggressive tumour with a tendency for local recurrence.
  • GCT constitutes 5% of all primary bone tumours.
  • Metachronous multicentric giant cell tumour of bone is a rare entity.
  • We report a young girl presenting with metachronous multicentric recurrent benign GCT, with the lesions involving the ipsilateral right hand and distal humerus.
  • [MeSH-major] Bone Neoplasms / pathology. Giant Cell Tumor of Bone / pathology. Hand Bones. Humerus. Neoplasms, Second Primary / pathology
  • [MeSH-minor] Adolescent. Female. Humans. Neoplasm Recurrence, Local

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21138229.001).
  • [ISSN] 0001-6462
  • [Journal-full-title] Acta orthopaedica Belgica
  • [ISO-abbreviation] Acta Orthop Belg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


44. Eckardt A, Swennen G, Barth EL, Brachvogel P: Long-term results after mandibular continuity resection in infancy: the role of autogenous rib grafts for mandibular restoration. J Craniofac Surg; 2006 Mar;17(2):255-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Reconstruction of mandibular defects after tumor resection in infants is a particular challenge.
  • Although autogenous rib grafts have no relevance nowadays for restoration of mandibular bone defects after ablative tumor surgery because of limited bone stock and the availability of other donor areas, they are a useful surgical alternative after tumor surgery in infants.
  • We here report on a 6-month, 5-year, and 10-year follow-up of three children who were diagnosed with benign tumors of the mandible with osseous destruction at the ages of 4 months, 6 months, and 2 years, respectively.
  • Histologic diagnoses were melanotic neuroectodermal tumor, hemangioendothelioma of the mandible, and ameloblastoma.
  • After continuity resection of the mandible, latero-mandibular bone defects were restored using autogenous rib grafts.
  • Further corrective surgery with bone augmentation or osseous distraction is required after completion of growth of the facial skeleton.
  • [MeSH-major] Bone Transplantation / methods. Mandible / surgery. Mandibular Neoplasms / rehabilitation. Oral Surgical Procedures / methods. Reconstructive Surgical Procedures / methods
  • [MeSH-minor] Ameloblastoma / rehabilitation. Ameloblastoma / surgery. Child, Preschool. Female. Follow-Up Studies. Hemangioendothelioma / rehabilitation. Hemangioendothelioma / surgery. Humans. Infant. Male. Maxillofacial Development. Neuroectodermal Tumor, Melanotic / rehabilitation. Neuroectodermal Tumor, Melanotic / surgery. Ribs / transplantation

  • MedlinePlus Health Information. consumer health - Bone Grafts.
  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16633171.001).
  • [ISSN] 1049-2275
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Ondik MP, Preston T, Towfighi J, Isaacson JE: Unilateral congenital facial nerve paralysis secondary to a benign epithelioid peripheral nerve sheath tumor. Otol Neurotol; 2007 Dec;28(8):1091-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unilateral congenital facial nerve paralysis secondary to a benign epithelioid peripheral nerve sheath tumor.
  • OBJECTIVE: A benign epithelioid peripheral nerve sheath tumor is described in the setting of congenital facial nerve (FN) paralysis.
  • INTERVENTIONS: Auditory brainstem evoked potential study, gadolinium-enhanced magnetic resonance imaging, temporal bone computed tomography, and transmastoid FN decompression with tumor resection.
  • MAIN OUTCOME MEASURES: Follow-up for tumor recurrence and postoperative FN function.
  • RESULTS: The child underwent a transmastoid FN exploration with resection of a 0.6-cm spherical tumor analyzed to be a benign epithelioid peripheral nerve sheath tumor.
  • CONCLUSION: Benign epithelioid peripheral nerve sheath tumor can cause congenital facial nerve palsy.
  • [MeSH-minor] Decompression, Surgical. Evoked Potentials, Auditory, Brain Stem / physiology. Facial Nerve / physiology. Facial Paralysis / congenital. Facial Paralysis / etiology. Female. Gadolinium. Humans. Infant. Magnetic Resonance Imaging. Temporal Bone / radiography

  • Genetic Alliance. consumer health - paralysis.
  • Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18084823.001).
  • [ISSN] 1531-7129
  • [Journal-full-title] Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
  • [ISO-abbreviation] Otol. Neurotol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] AU0V1LM3JT / Gadolinium
  •  go-up   go-down


46. Balke M, Streitbuerger A, Budny T, Henrichs M, Gosheger G, Hardes J: Treatment and outcome of giant cell tumors of the pelvis. Acta Orthop; 2009 Oct;80(5):590-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment and outcome of giant cell tumors of the pelvis.
  • BACKGROUND AND PURPOSE: Giant cell tumors (GCTs) of bone rarely affect the pelvis.
  • METHODS: 20 patients with histologically benign GCT of the pelvis were included in this study.
  • 9 tumors were primarily located in the iliosacral area, 6 in the acetabular area, and 5 in the ischiopubic area.
  • 3 patients with iliacal tumors were treated by wide resection.
  • Of the 6 patients with acetabular tumors, 1 secondarily received an endoprosthesis and 1 was primarily treated by hip transposition.
  • RESULTS: 1 patient with a pubic tumor developed a local recurrence 1 year after intralesional resection and additional curettage of the margins.
  • For tumors of the iliac wing, wide resection can be an alternative.
  • Surgical treatment of tumors affecting the acetabular region often results in functional impairment.
  • [MeSH-major] Bone Neoplasms / surgery. Giant Cell Tumor of Bone / surgery. Pelvic Bones
  • [MeSH-minor] Adult. Aged. Bone Cements. Bone Transplantation. Curettage. Embolization, Therapeutic / methods. Female. Follow-Up Studies. Humans. Ilium / pathology. Ilium / surgery. Male. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Radiotherapy, Adjuvant. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Orthop. 2008 Feb;79(1):86-93 [18283578.001]
  • [Cites] Spine (Phila Pa 1976). 2007 May 1;32(10):1107-15 [17471094.001]
  • [Cites] J Cancer Res Clin Oncol. 2009 Jan;135(1):149-58 [18521629.001]
  • [Cites] J Surg Oncol. 2009 Mar 1;99(3):169-72 [19072993.001]
  • [Cites] J Bone Joint Surg Am. 1999 Nov;81(11):1566-73 [10565648.001]
  • [Cites] Clin Orthop Relat Res. 2002 Apr;(397):248-58 [11953616.001]
  • [Cites] Cancer. 2002 Sep 15;95(6):1317-25 [12216101.001]
  • [Cites] Clin Orthop Relat Res. 2004 Jun;(423):196-207 [15232449.001]
  • [Cites] Clin Orthop Relat Res. 1969 Jan-Feb;62:187-91 [5774834.001]
  • [Cites] J Bone Joint Surg Am. 1978 Sep;60(6):731-46 [701308.001]
  • [Cites] Cancer. 1980 Oct 1;46(7):1641-9 [7417958.001]
  • [Cites] Acta Orthop Scand. 1984 Apr;55(2):209-14 [6369866.001]
  • [Cites] J Bone Joint Surg Am. 1986 Sep;68(7):1073-9 [3745247.001]
  • [Cites] J Bone Joint Surg Am. 1987 Jan;69(1):106-14 [3805057.001]
  • [Cites] N Engl J Med. 1987 Sep 3;317(10):588-93 [3475572.001]
  • [Cites] Clin Orthop Relat Res. 1987 Sep;(222):123-31 [3621712.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Nov;17(5):1085-8 [2808042.001]
  • [Cites] Chir Organi Mov. 1991 Oct-Dec;76(4):311-6 [1800042.001]
  • [Cites] Clin Orthop Relat Res. 1992 May;(278):29-36 [1563165.001]
  • [Cites] J Bone Joint Surg Am. 1993 Oct;75(10):1466-75 [8408135.001]
  • [Cites] J Bone Joint Surg Am. 1999 Jun;81(6):811-20 [10391546.001]
  • [Cites] Int Orthop. 2006 Dec;30(6):495-8 [16896875.001]
  • [Cites] J Cancer Res Clin Oncol. 2008 Sep;134(9):969-78 [18322700.001]
  • (PMID = 19916695.001).
  • [ISSN] 1745-3682
  • [Journal-full-title] Acta orthopaedica
  • [ISO-abbreviation] Acta Orthop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bone Cements
  • [Other-IDs] NLM/ PMC2823344
  •  go-up   go-down


47. Cueva del Castillo JF, Francisco Osuna J, Elizondo F, Pérez O, Pérez A, Hernández S, Mejía C: [Use of a xenoimplant for the treatment of bone defects, benign tumors, pseudoarthrosis and arthrodesis. Preliminary report]. Acta Ortop Mex; 2007 Jan-Feb;21(1):31-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Use of a xenoimplant for the treatment of bone defects, benign tumors, pseudoarthrosis and arthrodesis. Preliminary report].
  • [Transliterated title] Aplicación de xenoimplante para el tratamiento de defectos oseos, tumores benignos, seudoartrosis y artrodesis. (Reporte preliminar).
  • OBJECTIVE: To show that the ceramic produced at the Institute for Materials Research, National Autonomous University of Mexico, is an appropriate replacement of bone graft in patients with bone tumors, benign tumors, pseudoarthrosis and arthrodesis treated at "General Ignacio Zaragoza" Regional Hospital.
  • They underwent X-ray evaluation of bone healing using the Montoya classification.
  • The most frequent indication was arthrodesis in 10 patients (45.45%), pseudoarthrosis in 6 (27.27%), benign tumors in 3 (13.63%), and bone defects in 3 (13.63%).
  • Type II to type IV bone healing was observed in the sample.
  • DISCUSSION: The use of ceramic xenoimplants is appropriate as a replacement of bone graft in patients with arthrodesis and bone defects, thus avoiding the need for autologous bone graft.
  • [MeSH-major] Arthrodesis. Bone Neoplasms / surgery. Bone Transplantation. Pseudarthrosis / surgery. Transplantation, Heterologous

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Grafts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17695206.001).
  • [ISSN] 2306-4102
  • [Journal-full-title] Acta ortopédica mexicana
  • [ISO-abbreviation] Acta Ortop Mex
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


48. Murad M, Bari V, Rafique MZ, Ashraf K: Periosteal desmoid. J Pak Med Assoc; 2007 Jan;57(1):44-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Periosteal desmoid is a benign tumor like reactive fibrous lesion developed by repeated micro trauma.
  • We describe the case of a 14 year old boy with pain in his right knee who underwent plain radiography followed by radionuclide bone scan.
  • The final diagnosis was that of periosteal desmoid.
  • [MeSH-major] Athletic Injuries / diagnosis. Bone Diseases / diagnosis. Bone Neoplasms / diagnosis. Femur / injuries
  • [MeSH-minor] Adolescent. Diagnosis, Differential. Humans. Male

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Diseases.
  • MedlinePlus Health Information. consumer health - Sports Injuries.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17319422.001).
  • [ISSN] 0030-9982
  • [Journal-full-title] JPMA. The Journal of the Pakistan Medical Association
  • [ISO-abbreviation] J Pak Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


49. Gurates B, Parmaksiz C, Kilic G, Celik H, Kumru S, Simsek M: Treatment of symptomatic uterine leiomyoma with letrozole. Reprod Biomed Online; 2008 Oct;17(4):569-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Uterine leiomyomas are the most common benign tumours of the female genital tract, often necessitating hysterectomy.
  • The purpose of this study was to evaluate the effects of the non-steroidal aromatase inhibitor letrozole on uterine leiomyomas and on bone metabolism.
  • Lumbar spine bone mineral density and biochemical markers of bone metabolism were studied at the beginning and at the end of 3 months.
  • Letrozole significantly decreased uterine leiomyoma sizes (P < 0.01) and promptly benefited women with heavy menstrual bleeding associated with leiomyomas without changing bone mineral density.
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Aromatase Inhibitors / therapeutic use. Bone Density / drug effects. Bone and Bones / drug effects. Bone and Bones / metabolism. Female. Follicle Stimulating Hormone / blood. Humans. Luteinizing Hormone / blood. Organ Size / drug effects. Ovary / drug effects. Ovary / pathology. Pilot Projects. Tumor Burden / drug effects. Uterus / drug effects. Uterus / pathology

  • Genetic Alliance. consumer health - Uterine Fibroid.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • Hazardous Substances Data Bank. LETROZOLE .
  • Hazardous Substances Data Bank. MENOTROPINS .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18854113.001).
  • [ISSN] 1472-6491
  • [Journal-full-title] Reproductive biomedicine online
  • [ISO-abbreviation] Reprod. Biomed. Online
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Aromatase Inhibitors; 0 / Nitriles; 0 / Triazoles; 7LKK855W8I / letrozole; 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


50. Hayashi T, Horiuchi A, Sano K, Hiraoka N, Kanai Y, Shiozawa T, Tonegawa S, Konishi I: Mice-lacking LMP2, immuno-proteasome subunit, as an animal model of spontaneous uterine leiomyosarcoma. Protein Cell; 2010 Aug;1(8):711-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Uterine tumors are the most common type of gynecologic neoplasm.
  • Uterine leiomyosarcoma (LMS) is rare, accounting for 2% to 5% of tumors of the uterine body.
  • The development of gynecologic tumors is often correlated with female hormone secretion; however, the development of uterine LMS is not substantially correlated with hormonal conditions, and the risk factors are not yet known.
  • Radiographic evaluation combined with PET/CT can be useless in the diagnosis and surveillance of uterine LMS.
  • Importantly, a diagnostic biomarker, which distinguishes malignant LMS and benign tumor leiomyoma (LMA) is yet to be established.
  • [MeSH-minor] Animals. Biomarkers, Tumor / biosynthesis. Biomarkers, Tumor / genetics. Down-Regulation. Female. Gene Deletion. Humans. Interferon Regulatory Factor-1 / biosynthesis. Interferon Regulatory Factor-1 / genetics. Leiomyoma / metabolism. Mice. Mice, Knockout

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21203912.001).
  • [ISSN] 1674-8018
  • [Journal-full-title] Protein & cell
  • [ISO-abbreviation] Protein Cell
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Interferon Regulatory Factor-1; 144416-78-4 / LMP-2 protein; EC 3.4.22.- / Cysteine Endopeptidases; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  • [Other-IDs] NLM/ PMC4875197
  •  go-up   go-down


51. Sukkarieh F, Van Meerhaeghe A, Delrée P, Brasseur P: [Malignant peripheral nerve sheath tumor in the posterior mediastinum]. Rev Pneumol Clin; 2006 Jun;62(3):175-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant peripheral nerve sheath tumor in the posterior mediastinum].
  • [Transliterated title] Tumeur maligne de la gaine d'un nerf périphérique: une lésion rare du médiastin postérieur.
  • We report the case of a 52-year-old male patient who developed a malignant peripheral nerve sheath tumor (MPNST) localized in the posterior mediastinum.
  • The diagnosis of this rare tumor is difficult because the clinical presentation of the benign or malignant types is often similar, i.e. elective pain and bone erosions.
  • Histological diagnosis is required, but diagnosis can be compromised by the heterogeneous nature of the tumor.
  • [MeSH-major] Mediastinal Neoplasms / diagnosis. Mediastinal Neoplasms / surgery. Nerve Sheath Neoplasms / diagnosis. Nerve Sheath Neoplasms / surgery
  • [MeSH-minor] Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16840995.001).
  • [ISSN] 0761-8417
  • [Journal-full-title] Revue de pneumologie clinique
  • [ISO-abbreviation] Rev Pneumol Clin
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


52. Jung SN, Yim Y, Kwon H: Symmetric lipofibromatous hamartoma affecting digital nerves. Yonsei Med J; 2005 Feb 28;46(1):169-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lipofibromatous hamartoma of the nerve is a benign tumor, which affects the major nerves and their branches in the human body.
  • This tumor is often found in young adults and may go through a self- limiting course.
  • However, operation is indicated when the tumor size is large or when the associated nerve compressive symptoms are present.
  • With the aid of a microscope, we dissected and removed the tumor as much as possible without sacrificing the nerve.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Int. 2002 Nov;52(11):730-3 [12685550.001]
  • [Cites] Plast Reconstr Surg. 1968 Nov;42(5):403-13 [4301740.001]
  • [Cites] J Bone Joint Surg Am. 1969 Jul;51(5):984-90 [5798113.001]
  • [Cites] Ann Surg. 1972 Aug;176(2):217-22 [5077083.001]
  • [Cites] Radiographics. 1991 Jan;11(1):81-106 [1996399.001]
  • [Cites] Hand Clin. 1985 Aug;1(3):511-24 [3938454.001]
  • [Cites] J Hand Surg Am. 1988 Jan;13(1):67-75 [3351231.001]
  • [Cites] J Bone Joint Surg Br. 1989 Mar;71(2):331-2 [2538478.001]
  • [Cites] Acta Orthop Scand. 1990 Apr;61(2):181-2 [2360437.001]
  • [Cites] J Bone Joint Surg Am. 1979 Apr;61(3):393-7 [429410.001]
  • (PMID = 15744823.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Korea (South)
  • [Number-of-references] 11
  • [Other-IDs] NLM/ PMC2823046
  •  go-up   go-down


53. Atalar B, Miller RC, Dincbas FO, Geismar JH, Micke O, Akyurek S, Ozyar E: Adult langerhans cell histiocytosis of bones : a rare cancer network study. Acta Orthop Belg; 2010 Oct;76(5):663-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Langerhans Cell Histiocytosis (LCH) is an uncommon benign bone tumour typically seen in children.
  • The localization of tumours was skull bones in 12 (40%), lower extremity in 6 (20%), thoracic bones in 4 (133%), spine in 3 (10%), pelvis in 2 (6.7%) and multiple sites in 3 (10%) patients.
  • [MeSH-major] Bone Diseases / therapy. Histiocytosis, Langerhans-Cell / therapy


54. Zimering MB, Caldarella FA, White KE, Econs MJ: Persistent tumor-induced osteomalacia confirmed by elevated postoperative levels of serum fibroblast growth factor-23 and 5-year follow-up of bone density changes. Endocr Pract; 2005 Mar-Apr;11(2):108-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Persistent tumor-induced osteomalacia confirmed by elevated postoperative levels of serum fibroblast growth factor-23 and 5-year follow-up of bone density changes.
  • OBJECTIVE: To describe a case of persistent tumor-induced osteomalacia, determine whether serum fibroblast growth factor-23 (FGF-23) levels postoperatively indicate incomplete tumor resection, and report lumbar spine and forearm bone mineral density (BMD) changes during 5 years of follow-up.
  • METHODS: We present clinical, radiologic, histologic, and bone densitometry data as well as serum FGF-23 levels (determined with use of a novel C-terminal enzyme-linked immunosorbent assay) from the study patient and discuss these findings in the context of previous literature.
  • RESULTS: A 52-year-old man, who presented with muscle weakness and multiple fractures, was found to have low values for serum phosphorus, serum 1,25-dihydroxyvitamin D, and maximal tubular reabsorption of phosphate per glomerular filtration rate, a high level of serum alkaline phosphatase, and a normal serum concentration of parathyroid hormone, characteristic of tumor-induced osteomalacia.
  • Magnetic resonance imaging to evaluate an abnormality of the left foot revealed a soft tissue mass, biopsy of which confirmed the presence of a benign, phosphaturic, mesenchymal tumor.
  • The baseline serum FGF-23 level (2,050 RU/mL) was more than 17 times the upper limit of normal for adults (23 to 118 RU/mL) and decreased substantially within 1 day after partial resection of the tumor but remained above normal postoperatively.
  • BMD changes indicated rapid substantial recovery of vertebral BMD but ongoing loss of forearm bone density.
  • CONCLUSION: The serum FGF-23 level is high in a substantial proportion of patients with tumor-induced osteomalacia.
  • The postoperative above normal levels of serum FGF-23 correlated with known persistence of tumor in our study patient.
  • This result suggests that this assay can provide clinicians with rapid prognostic information in patients with known or suspected residual tumor.
  • BMD should be assessed at both appendicular and axial sites in patients with persistent tumor-induced osteomalacia.
  • [MeSH-major] Bone Density. Fibroblast Growth Factors / blood. Foot. Mesenchymoma / complications. Osteomalacia / etiology. Soft Tissue Neoplasms / complications
  • [MeSH-minor] Biomarkers / metabolism. Bone Remodeling. Follow-Up Studies. Forearm. Humans. Male. Middle Aged. Postoperative Period. Spine / metabolism

  • Genetic Alliance. consumer health - Osteomalacia.
  • MedlinePlus Health Information. consumer health - Bone Density.
  • MedlinePlus Health Information. consumer health - Foot Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15901526.001).
  • [ISSN] 1530-891X
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / fibroblast growth factor 23; 62031-54-3 / Fibroblast Growth Factors
  • [Number-of-references] 18
  •  go-up   go-down


55. Levi PA Jr, Kim DM, Harsfield SL, Jacobson ER: Squamous cell carcinoma presenting as an endodontic-periodontic lesion. J Periodontol; 2005 Oct;76(10):1798-804
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Regardless of advances in diagnosis and treatment during the past 40 years, the overall 5-year survival rates for oral and oropharyngeal squamous cancers have only slightly improved and remain around 50%.
  • Thus, the early diagnosis and treatment of carcinoma by health care providers are essential in achieving a good prognosis.
  • We report a case of invasive squamous cell carcinoma that presented as a benign endodontic-periodontic lesion with a 7-mm periodontal pocket on tooth #15 in a 40-year-old, non-smoking woman.
  • A periodontal flap surgical procedure was performed on teeth #13 to #15, and as there was bone erosion into the maxillary sinus, a biopsy of the soft tissue was submitted to the local hospital for histological analysis.
  • Bone invasion was also identified.
  • The patient remained free of tumor for 5 years after the initial presentation.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Gingival Neoplasms / pathology. Maxillary Neoplasms / pathology. Periodontal Cyst / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Maxillary Sinus Neoplasms / pathology. Neoplasm Invasiveness / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16253104.001).
  • [ISSN] 0022-3492
  • [Journal-full-title] Journal of periodontology
  • [ISO-abbreviation] J. Periodontol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Reize F, Buess E: Humeral osteochondroma causing a subscapularis tear: a rare source of shoulder dysfunction. Arch Orthop Trauma Surg; 2007 Jan;127(1):67-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The proximal humerus is a well-known site of predilection for the solitary osteochondroma-the most common benign bone tumor.
  • The patient was successfully treated by open resection of the tumor and reattachment of the tendon with suture anchors.
  • [MeSH-major] Bone Neoplasms / complications. Humerus. Osteochondroma / complications. Rotator Cuff / injuries

  • Genetic Alliance. consumer health - Osteochondroma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Rotator Cuff Injuries.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16927096.001).
  • [ISSN] 0936-8051
  • [Journal-full-title] Archives of orthopaedic and trauma surgery
  • [ISO-abbreviation] Arch Orthop Trauma Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


57. Lee SY, Lee SJ, Lee CS, Lee KR: Aneurysmal bone cyst originating from the first rib. Am J Surg; 2008 Jan;195(1):104-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aneurysmal bone cyst originating from the first rib.
  • Aneurysmal bone cyst is a benign tumor of the skeletal system and rare in the ribs.
  • The first rib containing tumor was removed.
  • Pathologic findings showed an aneurysmal bone cyst.
  • [MeSH-major] Bone Cysts, Aneurysmal / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18082549.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Stanić V, Vulović T, Stamenović D, Dordević G: Use of Marlex mesh with methylmethacrylate to repair large full-thickness defects after subtotal sternectomy caused by chondroma. Vojnosanit Pregl; 2008 Feb;65(2):175-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Sternal benign neoplasms are extremely rare.
  • Chondroma is a benign tumor of cartilage and can be single or multple.
  • CASE REPORT: We presented a case of 28-year-old woman with chondroma of the sternum treated by "en bloc" resection of the tumor (subtotal sternectomy).
  • [MeSH-major] Bone Neoplasms / surgery. Chondroma / surgery. Methylmethacrylate. Polypropylenes. Sternum. Surgical Mesh. Thoracic Wall / surgery

  • Genetic Alliance. consumer health - Chondroma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. Methyl methacrylate .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18365678.001).
  • [ISSN] 0042-8450
  • [Journal-full-title] Vojnosanitetski pregled
  • [ISO-abbreviation] Vojnosanit Pregl
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Serbia
  • [Chemical-registry-number] 0 / Polypropylenes; 196OC77688 / Methylmethacrylate
  •  go-up   go-down


59. Belli E, Mazzone N, Rendine G: Osteosarcoma radioinduced after adenoid cystic tumor of the parotid gland. J Craniofac Surg; 2010 Mar;21(2):387-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteosarcoma radioinduced after adenoid cystic tumor of the parotid gland.
  • Osteosarcoma can develop secondary to malignant transformation within a preexisting benign bone lesion, such as Paget disease, osteonecrosis, fibrous dysplasia, and chronic infection, or it can arise in previously irradiated areas.

  • Genetic Alliance. consumer health - Osteosarcoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20186080.001).
  • [ISSN] 1536-3732
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Cakarer S, Selvi F, Isler SC, Soluk M, Olgac V, Keskin C: Intraosseous lipoma of the mandible: a case report and review of the literature. Int J Oral Maxillofac Surg; 2009 Aug;38(8):900-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intraosseous lipoma is a benign tumor of the bone.
  • Diagnosis is based on clinical, radiological and histopathological features.
  • [MeSH-major] Lipoma / diagnosis. Mandibular Neoplasms / diagnosis
  • [MeSH-minor] Cementoma / diagnosis. Diagnosis, Differential. Female. Follow-Up Studies. Granuloma, Giant Cell / diagnosis. Humans. Mandibular Diseases / diagnosis. Middle Aged. Odontogenic Cysts / diagnosis. Odontogenic Tumors / diagnosis. Radiography, Panoramic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19386471.001).
  • [ISSN] 1399-0020
  • [Journal-full-title] International journal of oral and maxillofacial surgery
  • [ISO-abbreviation] Int J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Denmark
  • [Number-of-references] 10
  •  go-up   go-down


61. Zhan HW, Xu W, Ye XJ, Zhao CL, Zhang H, Li J, Yao Q, Zhang LJ: Application of FDG-PET for detection of malignant lesions in patients with elevated blood tumor markers but without a history of malignancy. Mol Med Rep; 2009 Sep-Oct;2(5):837-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Application of FDG-PET for detection of malignant lesions in patients with elevated blood tumor markers but without a history of malignancy.
  • A total of 132 patients with increased levels of blood tumor markers but without a prior history of malignancy were examined.
  • The results of FDG-PET and conventional work-up (CWU) including computed tomography (CT), ultrasonography, radionuclide bone scintigraphy and endoscopy were compared.
  • The final diagnosis was based on pathological evidence, other medical imaging results and a follow-up of at least 6 months.
  • There were 61 patients with malignant lesions and 71 without (benign lesions, n=35; healthy individuals, n=36).
  • The average number of elevated tumor markers and the average increase in these tumor markers were greater in the malignant group than in the non-malignant group.
  • FDG-PET imaging revealed that the maximum standardized uptake value (SUVmax) of the major lesion in patients with malignant (n=61) and benign (n=35) tumors was not significantly related to increased levels of tumor markers (r=0.10, p<0.05).
  • In conclusion, FDG-PET imaging is a valuable tool for the detection of malignant lesions in patients with increased levels of blood tumor markers but without a history of malignancy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21475910.001).
  • [ISSN] 1791-3004
  • [Journal-full-title] Molecular medicine reports
  • [ISO-abbreviation] Mol Med Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


62. Yarmish G, Klein MJ, Landa J, Lefkowitz RA, Hwang S: Imaging characteristics of primary osteosarcoma: nonconventional subtypes. Radiographics; 2010 Oct;30(6):1653-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Osteosarcoma (OS) is a common primary malignant tumor of bone that produces osteoid matrix.
  • According to the World Health Organization, OS of bone is classified into eight subtypes with distinct biologic behaviors and clinical outcomes: conventional, telangiectatic, small cell, low-grade central, secondary, parosteal, periosteal, and high-grade surface.
  • Imaging plays a crucial role in the diagnosis of each subtype of OS and ultimately in patients' survival because the diagnosis is based on a combination of histopathologic and imaging features.
  • Conventional OS is the most common subtype of OS and is readily identified at radiography as an intramedullary mass with immature cloudlike bone formation in the metaphyses of long bones.
  • The imaging features of less common subtypes of primary OS are variable and frequently overlap with those of multiple benign and malignant entities, creating substantial diagnostic challenges.
  • For accurate diagnosis, it is important to be aware of radiographic and cross-sectional imaging features that allow differentiation of each nonconventional subtype of OS from its mimics.
  • [MeSH-major] Bone Neoplasms / diagnosis. Diagnostic Imaging. Osteosarcoma / diagnosis
  • [MeSH-minor] Contrast Media. Diagnosis, Differential. Humans. Prognosis

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © RSNA, 2010.
  • (PMID = 21071381.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


63. Naama O, Gazzaz M, Akhaddar A, Belhachmi A, Asri A, Elmostarchid B, Elbouzidi A, Kadiri B, Boucetta M: Cavernous hemangioma of the skull: 3 case reports. Surg Neurol; 2008 Dec;70(6):654-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Intraosseous cavernous hemangiomas of the bone are uncommon tumors, accounting for 0.7% to 1% of all bone neoplasms.
  • Calvarial cavernous hemangioma is rare, comprising about 0.2% of all benign neoplasms of the skull.
  • CONCLUSION: Skull cavernous hemangiomas are rare benign tumors.
  • The preferred treatment is complete tumor removal with normal bony margins.
  • Consequently, the diagnosis is most often made during surgical resection.

  • Genetic Alliance. consumer health - Hemangioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18207223.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Bruners P, Penzkofer T, Günther RW, Mahnken A: [Percutaneous radiofrequency ablation of osteoid osteomas: technique and results]. Rofo; 2009 Aug;181(8):740-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Osteoid osteoma is a benign primary bone tumor that typically occurs in children and young adults.
  • Besides local pain, which is often worse at night, prompt relief due to medication with acetylsalicylic acid (ASS) is characteristic for this bone lesion.
  • MATERIALS AND METHODS: Using this technique, an often needle-shaped RF applicator is percutaneously placed into the tumor under image guidance.
  • Then a high-frequency alternating current is applied by the tip of the applicator which leads to ionic motion within the tissue resulting in local heat development and thus in thermal destruction of the surrounding tissue including the tumor.
  • [MeSH-major] Bone Neoplasms / surgery. Catheter Ablation / methods. Image Processing, Computer-Assisted. Imaging, Three-Dimensional. Magnetic Resonance Imaging / methods. Osteoma, Osteoid / surgery. Surgery, Computer-Assisted / methods. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19517335.001).
  • [ISSN] 1438-9010
  • [Journal-full-title] RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin
  • [ISO-abbreviation] Rofo
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 58
  •  go-up   go-down


65. Shintaku M, Nitta T, Matsubayashi K, Okamoto S: Ossifying choroid plexus papilloma recurring with features of atypical papilloma. Neuropathology; 2008 Apr;28(2):160-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient was a 46-year-old woman who underwent surgery for a 3-cm tumor occupying the fourth ventricle.
  • The tumor showed typical histopathological features of CPP, and the formation of psammoma bodies and mature bone trabeculae was prominent in the stroma.
  • The tumor recurred locally after a dormant period of 15 years, and the recurrent lesion showed invasion of the cerebellum as well as increased cellularity, cellular stratification, nuclear atypism, and mitotic activity, all of which were consistent with a diagnosis of "atypical" CPP.
  • The recurrent tumor did not show ossification of the stroma, although many psammoma bodies were found.
  • There have been very few reported cases of ossifying CPP, and all of the previous cases behaved in a benign fashion.
  • [MeSH-major] Neoplasm Recurrence, Local / pathology. Papilloma, Choroid Plexus / pathology

  • Genetic Alliance. consumer health - Choroid Plexus Papilloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18366349.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


66. Ando A, Hatori M, Hosaka M, Hagiwara Y, Kita A, Itoi E: Eosinophilic granuloma arising from the pelvis in children: A report of three cases. Ups J Med Sci; 2008;113(2):209-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eosinophilic granuloma (EG) is a benign tumor-like condition which is characterized by a clonal proliferation of Langerhans-type histiocytes and defined as a local form of Langerhans cell histiocytosis (LCH).
  • A status of EG in the bone is divided into acute and chronic phases.
  • Radiologically acute phase of EG is difficult to differentiate from a malignant bone tumor such as Ewing's sarcoma or acute osteomyelitis.
  • Chronic phase of EG may mimic a chronic osteomyelitis or a benign bone tumor.
  • These lesions resembled radiologically chronic osteomyelitis (Brodie's abscess) or a benign bone tumor and healed spontaneously after biopsy.
  • It was difficult to differentiate from a malignant tumor such as Ewing's sarcoma, or acute osteomyelitis.
  • Curettage of the affected site and bone grafting is usually accomplished.
  • [MeSH-major] Bone Neoplasms / complications. Eosinophilic Granuloma / etiology. Osteomyelitis / complications. Pelvis

  • Genetic Alliance. consumer health - Langerhans cell histiocytosis.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18509815.001).
  • [ISSN] 2000-1967
  • [Journal-full-title] Upsala journal of medical sciences
  • [ISO-abbreviation] Ups. J. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Sweden
  •  go-up   go-down


67. Miller JS, Warren EH, van den Brink MR, Ritz J, Shlomchik WD, Murphy WJ, Barrett AJ, Kolb HJ, Giralt S, Bishop MR, Blazar BR, Falkenburg JH: NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-Tumor/Leukemia Reaction. Biol Blood Marrow Transplant; 2010 May;16(5):565-86
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-Tumor/Leukemia Reaction.
  • The success of allogeneic hematopoietic stem cell transplantation (HSCT) depends on the infusion of benign stem cells as well as lymphocytes capable of participating in a graft-versus-tumor/leukemia (GVL) reaction.

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 American Society for Blood and Marrow Transplantation. All rights reserved.
  • [Cites] Blood. 2005 Apr 15;105(8):3051-7 [15632206.001]
  • [Cites] Blood. 2005 May 15;105(10):3945-50 [15692072.001]
  • [Cites] Blood. 2005 Jun 1;105(11):4191-9 [15701715.001]
  • [Cites] Science. 2006 Oct 6;314(5796):126-9 [16946036.001]
  • [Cites] Transplantation. 2006 Oct 27;82(8):1024-30 [17060849.001]
  • [Cites] Immunol Rev. 2006 Dec;214:130-42 [17100881.001]
  • [Cites] Nat Immunol. 2006 Dec;7(12):1334-42 [17057721.001]
  • [Cites] Inflamm Bowel Dis. 2007 Jan;13(1):2-11 [17206633.001]
  • [Cites] Blood. 2007 Feb 1;109(3):1103-12 [17023585.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2007 Feb;44(2):185-91 [17255829.001]
  • [Cites] J Clin Invest. 2007 Feb;117(2):492-501 [17273561.001]
  • [Cites] Nat Med. 2007 Mar;13(3):354-60 [17334371.001]
  • [Cites] Blood. 2007 May 1;109(9):4089-96 [17234742.001]
  • [Cites] Nat Rev Immunol. 2007 May;7(5):340-52 [17438575.001]
  • [Cites] Cancer Res. 2007 May 1;67(9):4507-13 [17483367.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2871-7 [17164341.001]
  • [Cites] Transplantation. 2007 May 15;83(9):1242-8 [17496542.001]
  • [Cites] J Immunol. 2007 Jun 1;178(11):6752-60 [17513722.001]
  • [Cites] Blood. 2007 Jul 1;110(1):433-40 [17371948.001]
  • [Cites] Bone Marrow Transplant. 2007 Aug;40(3):273-7 [17549053.001]
  • [Cites] Blood. 2007 Aug 1;110(3):1055-63 [17409267.001]
  • [Cites] Blood. 2007 Sep 15;110(6):1924-32 [17505014.001]
  • [Cites] Blood. 2007 Sep 15;110(6):2024-6 [17554057.001]
  • [Cites] Leukemia. 2007 Oct;21(10):2145-52 [17673900.001]
  • [Cites] Immunity. 2007 Sep;27(3):393-405 [17892848.001]
  • [Cites] Clin Cancer Res. 2007 Oct 15;13(20):6107-14 [17947475.001]
  • [Cites] Leukemia. 2007 Dec;21(12):2569-74 [17611558.001]
  • [Cites] Blood. 2007 Dec 15;110(13):4560-6 [17726164.001]
  • [Cites] Nat Rev Immunol. 2008 Jan;8(1):74-80 [18064049.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jan 29;105(4):1285-90 [18202175.001]
  • [Cites] Blood. 2008 Feb 15;111(4):2476-84 [18045967.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3837-42 [18316730.001]
  • [Cites] Blood. 2008 Apr 1;111(7):3884-92 [18223170.001]
  • [Cites] Immunol Rev. 2008 Apr;222:162-79 [18364001.001]
  • [Cites] Immunol Rev. 2008 Apr;222:180-91 [18364002.001]
  • [Cites] Annu Rev Immunol. 2008;26:57-79 [17953510.001]
  • [Cites] Blood. 2008 May 1;111(9):4817-26 [18299450.001]
  • [Cites] Blood. 2008 Jun 1;111(11):5326-33 [18276844.001]
  • [Cites] J Exp Med. 2008 Jul 7;205(7):1701-14 [18573906.001]
  • [Cites] Leukemia. 2008 Jul;22(7):1387-94 [18418406.001]
  • [Cites] Am J Transplant. 2008 Oct;8(10):2149-57 [18828773.001]
  • [Cites] J Immunol. 2008 Oct 15;181(8):5396-404 [18832696.001]
  • [Cites] Blood. 2009 Sep 17;114(12):2417-26 [19605850.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Sep 15;106(37):15825-30 [19717467.001]
  • [Cites] Eur J Immunol. 2009 Oct;39(10):2670-2 [19757440.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Oct 13;106(41):17469-74 [19805141.001]
  • [Cites] Blood. 2009 Oct 22;114(17):3684-92 [19706888.001]
  • [Cites] Blood. 2009 Oct 29;114(18):3793-802 [19724059.001]
  • [Cites] Blood. 2009 Dec 3;114(24):4919-27 [19749094.001]
  • [Cites] J Clin Invest. 2008 Jan;118(1):294-305 [18060041.001]
  • [Cites] Blood. 2010 Jan 7;115(1):151-3 [20056799.001]
  • [Cites] Blood. 2009 Dec 10;114(25):5216-24 [19786616.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2052-60 [12114403.001]
  • [Cites] J Clin Invest. 2002 Jul;110(2):185-92 [12122110.001]
  • [Cites] Immunol Rev. 2002 Aug;186:100-17 [12234366.001]
  • [Cites] Blood. 2008 Dec 1;112(12):4371-83 [19029455.001]
  • [Cites] Nat Immunol. 2009 Jan;10(1):29-37 [19043418.001]
  • [Cites] J Immunol. 2009 Jan 1;182(1):240-9 [19109155.001]
  • [Cites] Blood. 2009 Jan 15;113(3):726-32 [18945962.001]
  • [Cites] Nat Immunol. 2009 Feb;10(2):149-57 [19136960.001]
  • [Cites] J Exp Med. 2009 Jan 16;206(1):25-34 [19103877.001]
  • [Cites] Blood. 2009 Jan 22;113(4):875-82 [18922853.001]
  • [Cites] Nature. 2009 Jan 29;457(7229):557-61 [19136945.001]
  • [Cites] Cancer Res. 2009 Feb 15;69(4):1553-60 [19201693.001]
  • [Cites] Nat Rev Immunol. 2009 Mar;9(3):162-74 [19197294.001]
  • [Cites] Cancer Res. 2009 Mar 15;69(6):2514-22 [19276342.001]
  • [Cites] Blood. 2009 Mar 19;113(12):2851-8 [18997170.001]
  • [Cites] J Immunol. 2009 Apr 15;182(8):4572-80 [19342631.001]
  • [Cites] Trends Immunol. 2009 Apr;30(4):143-9 [19282243.001]
  • [Cites] Blood. 2009 Apr 16;113(16):3865-74 [19168788.001]
  • [Cites] Cytotherapy. 2009;11(3):341-55 [19308771.001]
  • [Cites] Cancer Res. 2009 May 1;69(9):4010-7 [19383914.001]
  • [Cites] J Immunol. 2009 May 15;182(10):5938-48 [19414745.001]
  • [Cites] Blood. 2009 May 21;113(21):5041-8 [18809759.001]
  • [Cites] Clin Cancer Res. 2009 Jul 15;15(14):4759-68 [19567591.001]
  • [Cites] Cancer Immunol Immunother. 2009 Oct;58(10):1535-44 [19562338.001]
  • [Cites] Biol Blood Marrow Transplant. 2009 Sep;15(9):1005-13 [19660713.001]
  • [Cites] J Immunol. 2009 Aug 15;183(4):2475-83 [19635913.001]
  • [Cites] Blood. 2009 Sep 10;114(11):2323-32 [19617579.001]
  • [Cites] Immunol Res. 2009;45(1):46-61 [18629449.001]
  • [Cites] Blood. 2004 Jun 1;103(11):4353-61 [14982874.001]
  • [Cites] Nat Immunol. 2004 Jul;5(7):678-84 [15224093.001]
  • [Cites] Immunol Rev. 2004 Jun;199:9-26 [15233723.001]
  • [Cites] J Exp Med. 2004 Jul 19;200(2):149-57 [15249593.001]
  • [Cites] Leukemia. 2004 Aug;18(8):1401-5 [15215873.001]
  • [Cites] Bone Marrow Transplant. 2004 Oct;34(8):703-9 [15322566.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Mar;86(6):1963-7 [2784565.001]
  • [Cites] J Exp Med. 1991 Jul 1;174(1):27-33 [2056279.001]
  • [Cites] Science. 1992 Dec 11;258(5089):1795-8 [1465616.001]
  • [Cites] Nature. 1994 Feb 17;367(6464):645-8 [7509044.001]
  • [Cites] J Immunol. 1994 Apr 1;152(7):3282-93 [7511642.001]
  • [Cites] N Engl J Med. 1995 Jan 19;332(3):143-9 [7800006.001]
  • [Cites] J Clin Invest. 1995 Aug;96(2):877-83 [7635982.001]
  • [Cites] J Exp Med. 1996 Jun 1;183(6):2645-56 [8676085.001]
  • [Cites] Blood. 1996 Oct 1;88(7):2450-7 [8839835.001]
  • [Cites] J Immunol. 1997 Jan 1;158(1):29-39 [8977172.001]
  • [Cites] Nat Med. 1997 Jul;3(7):730-7 [9212098.001]
  • [Cites] J Clin Invest. 1997 Aug 15;100(4):855-66 [9259585.001]
  • [Cites] Blood. 1997 Oct 1;90(7):2529-34 [9326217.001]
  • [Cites] J Exp Med. 1997 Dec 15;186(12):2057-62 [9396776.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jan 6;95(1):258-63 [9419363.001]
  • [Cites] J Immunol. 1998 May 1;160(9):4225-31 [9574523.001]
  • [Cites] Nat Med. 1998 May;4(5):627-30 [9585241.001]
  • [Cites] Blood. 1998 Dec 1;92(11):4150-66 [9834220.001]
  • [Cites] Cell Immunol. 1998 Dec 15;190(2):167-72 [9878117.001]
  • [Cites] J Immunol. 1999 Apr 15;162(8):4373-6 [10201970.001]
  • [Cites] Blood. 1999 Jul 1;94(1):333-9 [10381530.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8639-44 [10411928.001]
  • [Cites] J Clin Invest. 1999 Aug;104(4):459-67 [10449438.001]
  • [Cites] Leukemia. 2005 Jan;19(1):83-90 [15526024.001]
  • [Cites] J Immunol. 2005 Jan 15;174(2):600-4 [15634875.001]
  • [Cites] Blood. 2005 Mar 1;105(5):2227-34 [15522961.001]
  • [Cites] Nature. 2005 Feb 24;433(7028):887-92 [15711573.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2594-600 [15536148.001]
  • [Cites] Blood. 2005 Apr 1;105(7):2973-8 [15613541.001]
  • [Cites] Blood. 2005 Apr 15;105(8):3372-80 [15618467.001]
  • [Cites] Cancer Res. 2002 Oct 1;62(19):5517-22 [12359762.001]
  • [Cites] Science. 2002 Oct 25;298(5594):850-4 [12242449.001]
  • [Cites] Blood. 2002 Nov 15;100(10):3825-7 [12393440.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4259-65 [12393464.001]
  • [Cites] Blood. 2003 Jan 15;101(2):766-70 [12393700.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2742-7 [12601144.001]
  • [Cites] Science. 2003 Apr 11;300(5617):339-42 [12690202.001]
  • [Cites] Blood. 2003 May 1;101(9):3741-8 [12521997.001]
  • [Cites] J Exp Med. 2003 May 5;197(9):1141-51 [12732656.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2561-8 [12750280.001]
  • [Cites] J Exp Med. 2003 May 19;197(10):1279-89 [12743171.001]
  • [Cites] Blood. 2003 Aug 1;102(3):814-9 [12689936.001]
  • [Cites] J Immunol. 2003 Aug 1;171(3):1272-7 [12874215.001]
  • [Cites] Nat Immunol. 2003 Oct;4(10):1009-15 [14502286.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2892-900 [12829610.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14163-8 [14615582.001]
  • [Cites] J Clin Invest. 2003 Dec;112(12):1880-6 [14679183.001]
  • [Cites] Blood. 2004 Jan 1;103(1):347-52 [12969970.001]
  • [Cites] Blood. 2004 Jan 15;103(2):656-63 [14563636.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1534-41 [14551132.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1542-7 [14563643.001]
  • [Cites] Tissue Antigens. 2004 Mar;63(3):204-11 [14989709.001]
  • [Cites] Annu Rev Immunol. 2004;22:745-63 [15032595.001]
  • [Cites] Blood. 2004 Apr 1;103(7):2860-1; author reply 2862 [15033884.001]
  • [Cites] J Exp Med. 2004 Apr 19;199(8):1133-42 [15096539.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5211-20 [15958566.001]
  • [Cites] N Engl J Med. 2005 Jun 16;352(24):2499-507 [15958805.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9571-6 [15980149.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):709-13 [16079848.001]
  • [Cites] J Immunol. 2005 Aug 15;175(4):2244-51 [16081792.001]
  • [Cites] J Immunol. 2005 Oct 1;175(7):4392-9 [16177080.001]
  • [Cites] Blood. 2005 Nov 1;106(9):3285-92 [15956289.001]
  • [Cites] Blood. 2005 Nov 1;106(9):3322-30 [16037386.001]
  • [Cites] Blood. 2005 Nov 15;106(10):3666-72 [16046526.001]
  • [Cites] Nat Med. 2005 Nov;11(11):1244-9 [16227991.001]
  • [Cites] J Clin Invest. 2005 Dec;115(12):3506-16 [16322791.001]
  • [Cites] J Clin Oncol. 2005 Dec 10;23(35):8968-77 [16204013.001]
  • [Cites] Leukemia. 2006 Feb;20(2):371-4 [16357839.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1703-11 [16291587.001]
  • [Cites] Nature. 2006 Feb 9;439(7077):682-7 [16382236.001]
  • [Cites] J Immunol. 2006 Mar 1;176(5):2808-16 [16493037.001]
  • [Cites] N Engl J Med. 2006 Mar 2;354(9):899-910 [16510744.001]
  • [Cites] N Engl J Med. 2006 Mar 2;354(9):911-23 [16510745.001]
  • [Cites] Science. 2006 Mar 31;311(5769):1924-7 [16484453.001]
  • [Cites] J Immunol. 2006 Jun 15;176(12):7394-401 [16751384.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4954-60 [16497972.001]
  • [Cites] Blood. 2006 Jul 15;108(2):756-62 [16551963.001]
  • [Cites] Adv Cancer Res. 2006;95:1-30 [16860654.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Aug;12(8):876-84 [16864058.001]
  • [Cites] Immunity. 2006 Aug;25(2):331-42 [16901727.001]
  • [Cites] Eur J Immunol. 1999 Nov;29(11):3562-70 [10556810.001]
  • [Cites] J Immunol. 2000 May 1;164(9):4564-8 [10779758.001]
  • [Cites] Blood. 2000 Aug 1;96(3):1047-55 [10910921.001]
  • [Cites] Nat Med. 2000 Sep;6(9):1018-23 [10973322.001]
  • [Cites] J Clin Invest. 2000 Sep;106(5):705-14 [10974024.001]
  • [Cites] J Immunol. 2001 Mar 1;166(5):3174-83 [11207270.001]
  • [Cites] Nature. 2001 Jan 4;409(6816):97-101 [11343121.001]
  • [Cites] J Immunol. 2001 Nov 1;167(9):4981-6 [11673505.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):931-6 [11792864.001]
  • [Cites] Nat Immunol. 2002 Feb;3(2):135-42 [11812990.001]
  • [Cites] Blood. 2002 Apr 15;99(8):3027-32 [11929796.001]
  • [Cites] Blood. 2002 May 1;99(9):3179-87 [11964281.001]
  • [Cites] Nat Rev Immunol. 2002 Apr;2(4):273-81 [12001998.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4610-7 [12036895.001]
  • (PMID = 20152921.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA065493; United States / NCI NIH HHS / CA / CA111412-05; United States / NCI NIH HHS / CA / P01 CA111412-05; United States / NCI NIH HHS / CA / P01 CA111412; United States / NCI NIH HHS / CA / P01 CA142106
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS179009; NLM/ PMC2858433
  •  go-up   go-down


68. Yu Y, Fuhr J, Boye E, Gyorffy S, Soker S, Atala A, Mulliken JB, Bischoff J: Mesenchymal stem cells and adipogenesis in hemangioma involution. Stem Cells; 2006 Jun;24(6):1605-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hemangioma is a benign tumor of infancy whose hallmark is rapid growth during the first year of life followed by slow regression during early childhood.
  • We postulated that mesenchymal stem cells (MSCs) reside in the tumor and preferentially differentiate into adipocytes.
  • These hemangioma-derived MSCs (Hem-MSCs) are similar to MSCs obtained from human bone marrow, expressing the cell surface markers SH2 (CD105), SH3, SH4, CD90, CD29, smooth muscle alpha-actin, and CD133 but not the hematopoietic markers CD45 and CD14 or the hematopoietic/endothelial markers CD34, CD31, and kinase insert domain receptor (KDR).
  • The numbers of adipogenic Hem-MSCs were higher in proliferating-phase than in involuting-phase tumors and higher than in normal infantile skin.
  • [MeSH-minor] Antigens, Neoplasm / metabolism. Cell Differentiation. Cell Proliferation. Clone Cells / pathology. Female. Granuloma, Pyogenic / genetics. Granuloma, Pyogenic / immunology. Granuloma, Pyogenic / pathology. Humans. Infant. Infant, Newborn. Neoplasm Regression, Spontaneous / pathology. Neoplastic Stem Cells / pathology. Skin Neoplasms / genetics. Skin Neoplasms / immunology. Skin Neoplasms / pathology. X Chromosome Inactivation

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16456130.001).
  • [ISSN] 1066-5099
  • [Journal-full-title] Stem cells (Dayton, Ohio)
  • [ISO-abbreviation] Stem Cells
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / P01 AR 048564
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm
  •  go-up   go-down


69. Kara C, Kutlu AO, Tosun MS, Apaydin S, Senel F: Sertoli cell tumor causing prepubertal gynecomastia in a boy with peutz-jeghers syndrome: the outcome of 1-year treatment with the aromatase inhibitor testolactone. Horm Res; 2005;63(5):252-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sertoli cell tumor causing prepubertal gynecomastia in a boy with peutz-jeghers syndrome: the outcome of 1-year treatment with the aromatase inhibitor testolactone.
  • Peutz-Jeghers syndrome (PJS) is a rare disorder characterized by benign intestinal hamartomatous polyps and mucocutaneous pigmentation, and with an increased risk for intestinal and extra-intestinal neoplasms.
  • Sertoli cell tumors in boys with PJS have been increasingly recognized as a cause of prepubertal gynecomastia.
  • We report on a 7.25-year-old boy with PJS, bilateral gynecomastia, Sertoli cell tumor and nephrocalcinosis, and present the outcome of 1-year treatment with the aromatase inhibitor testolactone.
  • Histopathological examination was consistent with Sertoli cell tumors.
  • One-year treatment with testolactone reduced the breast base diameter from 7 to 3 cm, and bone age advanced 1.2 years during this period.
  • [MeSH-major] Aromatase Inhibitors / therapeutic use. Gynecomastia / complications. Peutz-Jeghers Syndrome / complications. Sertoli Cell Tumor / complications. Testicular Neoplasms / complications. Testolactone / therapeutic use

  • Genetic Alliance. consumer health - Peutz Jeghers syndrome.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. TESTOLACTONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15947469.001).
  • [ISSN] 0301-0163
  • [Journal-full-title] Hormone research
  • [ISO-abbreviation] Horm. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Aromatase Inhibitors; 6J9BLA949Q / Testolactone
  •  go-up   go-down


70. Krstulja M, Car A, Bonifacić D, Braut T, Kujundzić M: Nasopharyngeal angiofibroma with intracellular accumulation of SPARC - a hypothesis (SPARC in nasopharyngeal angiofibroma). Med Hypotheses; 2008;70(3):600-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nasopharyngeal angiofibroma is a histologically benign tumor composed of stroma and vessels.
  • Some nasopharyngeal angiofibromas are resistant to surgical therapy because of extensive growth and occasionally bone destruction.
  • Such molecule(s) may also regulate bone homing of the tumor.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17681430.001).
  • [ISSN] 0306-9877
  • [Journal-full-title] Medical hypotheses
  • [ISO-abbreviation] Med. Hypotheses
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Osteonectin
  •  go-up   go-down


71. Daigeler A, Vogt PM, Busch K, Pennekamp W, Weyhe D, Lehnhardt M, Steinstraesser L, Steinau HU, Kuhnen C: Elastofibroma dorsi--differential diagnosis in chest wall tumours. World J Surg Oncol; 2007;5:15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elastofibroma dorsi--differential diagnosis in chest wall tumours.
  • BACKGROUND: Elastofibromas are benign soft tissue tumours mostly of the infrascapular region between the thoracic wall, the serratus anterior and the latissimus dorsi muscle with a prevalence of up to 24% in the elderly.
  • The tumor sizes ranged from 3 to 13 cm.
  • CONCLUSION: In differential diagnosis of soft tissue tumors located at this specific site, elastofibroma should be considered as likely diagnosis.
  • Due to its benign behaviour, the tumor should be resected only in symptomatic patients.
  • [MeSH-minor] Aged. Biopsy, Needle. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Immunohistochemistry. Magnetic Resonance Imaging / methods. Male. Middle Aged. Retrospective Studies. Risk Assessment. Sampling Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 1986 Aug;160(2):341-2 [3726110.001]
  • [Cites] Hum Pathol. 1987 May;18(5):424-9 [3552953.001]
  • [Cites] Am J Surg Pathol. 1985 Mar;9(3):233-7 [2581462.001]
  • [Cites] Spine (Phila Pa 1976). 1983 Oct;8(7):800-2 [6665583.001]
  • [Cites] Indian Heart J. 1987 May-Jun;39(3):237-9 [3447963.001]
  • [Cites] Orthop Rev. 1989 Mar;18(3):329-33 [2652048.001]
  • [Cites] J Comput Assist Tomogr. 1989 Jul-Aug;13(4):701-3 [2745793.001]
  • [Cites] J Thorac Cardiovasc Surg. 1989 Aug;98(2):234-8 [2755156.001]
  • [Cites] Skeletal Radiol. 1989;18(8):619-22 [2609196.001]
  • [Cites] J Belge Radiol. 1991;74(1):37-9 [2022606.001]
  • [Cites] Acta Cytol. 1992 Jul-Aug;36(4):559-62 [1636353.001]
  • [Cites] AJR Am J Roentgenol. 1992 Sep;159(3):575-9 [1503030.001]
  • [Cites] Ann Thorac Surg. 1992 Oct;54(4):774-6 [1417241.001]
  • [Cites] Skeletal Radiol. 1993;22(2):121-3 [8438182.001]
  • [Cites] Diagn Cytopathol. 1994;10(3):242-4 [8050332.001]
  • [Cites] Am J Surg Pathol. 1995 Mar;19(3):364-7 [7872435.001]
  • [Cites] J Comput Assist Tomogr. 1995 Jul-Aug;19(4):601-3 [7622692.001]
  • [Cites] Radiologe. 1995 Sep;35(9):611-5 [8588045.001]
  • [Cites] Eur J Surg Oncol. 1996 Feb;22(1):93-6 [8846878.001]
  • [Cites] AJR Am J Roentgenol. 1996 Sep;167(3):683-7 [8751681.001]
  • [Cites] Clin Orthop Relat Res. 1996 Apr;(325):245-50 [8998883.001]
  • [Cites] AJR Am J Roentgenol. 1997 Oct;169(4):1113-5 [9308474.001]
  • [Cites] Eur J Radiol. 1998 Jul;27(3):264-7 [9717644.001]
  • [Cites] J Radiol. 1998 Jun;79(6):549-51 [9757282.001]
  • [Cites] AJR Am J Roentgenol. 1998 Oct;171(4):977-80 [9762978.001]
  • [Cites] Clin Orthop Relat Res. 1999 Jul;(364):213-9 [10416411.001]
  • [Cites] Acta Pathol Microbiol Scand Suppl. 1961;51(Suppl 144):83-4 [13789598.001]
  • [Cites] Am J Clin Pathol. 1962 May;37:499-506 [13916810.001]
  • [Cites] Joint Bone Spine. 2004 Nov;71(6):536-41 [15589435.001]
  • [Cites] Acta Orthop Belg. 2006 Apr;72(2):237-42 [16768275.001]
  • [Cites] Int J Dermatol. 2006 Sep;45(9):1100-3 [16961522.001]
  • [Cites] Ann Thorac Surg. 2006 Oct;82(4):1501-4 [16996964.001]
  • [Cites] Cancer. 1982 Nov 1;50(9):1794-805 [7116305.001]
  • [Cites] Surg Today. 2000;30(2):147-52 [10664338.001]
  • [Cites] J Comput Assist Tomogr. 2000 Mar-Apr;24(2):288-92 [10752895.001]
  • [Cites] Clin Orthop Relat Res. 2001 Jul;(388):200-4 [11451120.001]
  • [Cites] Semin Musculoskelet Radiol. 2001 Jun;5(2):103-5 [11500149.001]
  • [Cites] Skeletal Radiol. 2003 Feb;32(2):116-8 [12589494.001]
  • [Cites] Diagn Cytopathol. 2003 Dec;29(6):327-33 [14648789.001]
  • [Cites] J Exp Clin Cancer Res. 2003 Dec;22(4):565-9 [15053298.001]
  • [Cites] AJR Am J Roentgenol. 2004 Jul;183(1):35-7 [15208104.001]
  • [Cites] Cancer. 1969 Jan;23(1):42-63 [4303173.001]
  • [Cites] Cancer. 1969 Feb;23(2):406-15 [5764979.001]
  • [Cites] J Bone Joint Surg Am. 1973 Mar;55(2):409-12 [4121211.001]
  • [Cites] Br J Surg. 1974 Jul;61(7):583-4 [4846152.001]
  • [Cites] Br J Radiol. 1974 Sep;47(561):621-3 [4424819.001]
  • [Cites] Acta Pathol Microbiol Scand A. 1975 Jan;83(1):87-108 [1124654.001]
  • [Cites] Cancer. 1977 Aug;40(2):728-35 [890655.001]
  • [Cites] Hum Pathol. 1980 May;11(3):257-62 [7399517.001]
  • (PMID = 17280612.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1797045
  • [General-notes] NLM/ Original DateCompleted: 20070808
  •  go-up   go-down


72. Ringe KI, Schirg E, Rosenthal H, Berendonk H, Galanski M: Unilateral tibia vara in a toddler caused by focal fibrocartilaginous dysplasia. J Radiol Case Rep; 2009;3(9):14-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Focal fibrocartilaginous dysplasia (FFCD) of the tibia is a rare tumor like lesion probably caused by a failure of differentiation in the pes anserinus area.
  • In most cases this benign condition undergoes spontaneous resolution.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22470683.001).
  • [ISSN] 1943-0922
  • [Journal-full-title] Journal of radiology case reports
  • [ISO-abbreviation] J Radiol Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3303332
  • [Keywords] NOTNLM ; FFCD / Focal fibrocartilaginous dysplasia / tibia vara
  •  go-up   go-down


73. Aydoğdu K, Findik G, Agackiran Y, Kaya S, Karaoglanoglu N, Tastepe I: Primary tumors of the ribs; experience with 78 patients. Interact Cardiovasc Thorac Surg; 2009 Aug;9(2):251-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary tumors of the ribs; experience with 78 patients.
  • A retrospective study of primary tumors of the ribs (PTR) was conducted to review their clinical, radiological, and pathological features, as well as the early and long-term results of surgical management.
  • Forty-nine (63%) of the patients had benign lesions and 29 (37%) had malignant lesions.
  • In the group with malignant tumors, the main symptom was pain, but in the group with benign tumors, the main symptom was swelling.
  • Eight cases in the benign group and four cases in the malignant group were asymptomatic (accidental radiological findings in recruitment centers).
  • Most of the patients with PTR had benign lesions.
  • Surgery must consist of wide resection with tumor-free margins in order to provide the best chance for cure in both benign and malignant lesions.
  • [MeSH-major] Bone Neoplasms. Ribs

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19447801.001).
  • [ISSN] 1569-9285
  • [Journal-full-title] Interactive cardiovascular and thoracic surgery
  • [ISO-abbreviation] Interact Cardiovasc Thorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


74. Lehnhardt M, Daigeler A, Homann HH, Hauser J, Langer S, Steinsträsser L, Soimaru C, Puls A, Steinau HU: [Importance of specialized centers in diagnosis and treatment of extremity-soft tissue sarcomas. Review of 603 cases]. Chirurg; 2009 Apr;80(4):341-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Importance of specialized centers in diagnosis and treatment of extremity-soft tissue sarcomas. Review of 603 cases].
  • Correct histopathologic diagnosis is essential for adequate treatment of soft tissue sarcomas.
  • Due to the disorder's rarity, multitude of subgroups, sometimes varying histopathologic appearance, and occasionally inadequate biopsy specimens, diagnosis and grading are challenging.
  • The records of 603 patients with soft tissue tumors of the extremities were reviewed concerning mismatches in primary and definite diagnoses relating to entity, evaluation of primary or recurrent tumor specimens, and the diagnosing pathology institution.
  • In the eight most frequent sarcoma types, malignant peripheral nerve sheath tumors and leiomyosarcoma had the highest rates of false primary diagnosis, 78.4% and 74.2% of cases, respectively.
  • [MeSH-major] Cancer Care Facilities. Extremities / surgery. Hospitals, Special. Hospitals, University. Sarcoma / diagnosis. Sarcoma / surgery. Soft Tissue Neoplasms / diagnosis. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Child. Combined Modality Therapy. Diagnostic Errors. Female. Germany. Histiocytoma, Benign Fibrous / diagnosis. Histiocytoma, Benign Fibrous / pathology. Histiocytoma, Benign Fibrous / surgery. Humans. Leiomyosarcoma / diagnosis. Leiomyosarcoma / pathology. Leiomyosarcoma / surgery. Liposarcoma / diagnosis. Liposarcoma / pathology. Liposarcoma / surgery. Male. Middle Aged. Neoplasm Staging. Nerve Sheath Neoplasms / diagnosis. Nerve Sheath Neoplasms / pathology. Nerve Sheath Neoplasms / surgery. Radiotherapy, Adjuvant. Referral and Consultation. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 2001 Oct;116(4):473-6 [11601130.001]
  • [Cites] Cancer Treat Res. 2004;120:43-63 [15217217.001]
  • [Cites] Invest New Drugs. 2006 May;24(3):249-53 [16133789.001]
  • [Cites] Int J Hyperthermia. 2006 May;22(3):235-9 [16754344.001]
  • [Cites] Arch Pathol Lab Med. 1995 Jun;119(6):514-7 [7605166.001]
  • [Cites] Curr Oncol Rep. 2005 Jul;7(4):300-6 [15946590.001]
  • [Cites] Can J Surg. 1988 Nov;31(6):404-6 [3179848.001]
  • [Cites] Am J Surg Pathol. 1992 Mar;16(3):213-28 [1317996.001]
  • [Cites] Chirurg. 2001 May;72(5):501-13 [11383061.001]
  • [Cites] J Surg Oncol. 2008 Jan 1;97(1):40-3 [17918224.001]
  • [Cites] Chirurg. 2004 Dec;75(12):1182-90 [15309264.001]
  • [Cites] Ann Diagn Pathol. 1999 Feb;3(1):48-61 [9990113.001]
  • [Cites] Curr Top Pathol. 1995;89:123-51 [7882706.001]
  • [Cites] Eur J Cancer. 2002 Mar;38(4):556-9 [11872349.001]
  • [Cites] Curr Treat Options Oncol. 2004 Dec;5(6):451-62 [15509479.001]
  • [Cites] Pathol Res Pract. 1988 Nov;183(6):698-705 [2851775.001]
  • [Cites] Histopathology. 2006 Jan;48(1):3-12 [16359532.001]
  • [Cites] Invest New Drugs. 2003 Nov;21(4):481-6 [14586217.001]
  • [Cites] Acta Orthop Scand Suppl. 2004 Apr;75(311):77-86 [15188669.001]
  • [Cites] Cancer. 1999 Dec 1;86(11):2426-35 [10590387.001]
  • [Cites] Clin Orthop Relat Res. 1999 Nov;(368):212-9 [10613171.001]
  • [Cites] Bull Cancer. 2001 Aug;88(8):765-73 [11578945.001]
  • [Cites] Curr Oncol Rep. 2006 Jul;8(4):305-9 [17254531.001]
  • [Cites] Cancer. 1986 Jul 15;58(2):306-9 [3719523.001]
  • [Cites] J Bone Joint Surg Am. 1996 May;78(5):656-63 [8642021.001]
  • [Cites] Hum Pathol. 2002 Jan;33(1):111-5 [11823981.001]
  • [Cites] Chirurg. 2007 Jan;78(1):62-4 [16786340.001]
  • [Cites] Lancet Oncol. 2000 Oct;1:75-85 [11905672.001]
  • [Cites] Crit Rev Oncol Hematol. 2002 Feb;41(2):157-67 [11856592.001]
  • [Cites] Expert Rev Anticancer Ther. 2004 Apr;4(2):237-46 [15056054.001]
  • [Cites] Mod Pathol. 2007 Jul;20(7):749-59 [17464315.001]
  • [Cites] Verh Dtsch Ges Pathol. 2006;90:59-72 [17867581.001]
  • [Cites] Cancer Treat Res. 1993;67:1-22 [8102867.001]
  • [Cites] Am J Clin Pathol. 2000 Sep;114(3):329-35 [10989631.001]
  • [Cites] Br J Cancer. 1991 Aug;64(2):315-20 [1892759.001]
  • (PMID = 18523742.001).
  • [ISSN] 1433-0385
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


75. Magnies M, Giezek F, Jouandeau V, Custoza E: [Multiple calvarial cavernous hemangiomas]. J Neuroradiol; 2009 Dec;36(5):294-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Multiples hémangiomes caverneux de la voûte du crâne.
  • This benign tumor, arising from the intrinsic vasculature of bone, grows slowly over a period of years before it causes symptoms such as headaches or localized compression.

  • Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19403170.001).
  • [ISSN] 0150-9861
  • [Journal-full-title] Journal of neuroradiology. Journal de neuroradiologie
  • [ISO-abbreviation] J Neuroradiol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Contrast Media; AU0V1LM3JT / Gadolinium
  •  go-up   go-down


76. Simpfendorfer CS, Ilaslan H, Davies AM, James SL, Obuchowski NA, Sundaram M: Does the presence of focal normal marrow fat signal within a tumor on MRI exclude malignancy? An analysis of 184 histologically proven tumors of the pelvic and appendicular skeleton. Skeletal Radiol; 2008 Sep;37(9):797-804
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does the presence of focal normal marrow fat signal within a tumor on MRI exclude malignancy? An analysis of 184 histologically proven tumors of the pelvic and appendicular skeleton.
  • OBJECTIVE: The aim of this study was to determine if the presence of focal normal bone marrow fat signal within a tumor on magnetic resonance imaging excludes malignancy.
  • MATERIALS AND METHODS: One hundred eighty-four histologically proven tumors with available magnetic resonance imaging (MRI) of the appendicular skeleton and pelvis from 184 patients were collected and reviewed at two separate institutions.
  • There were 111 malignant and 73 benign tumors.
  • Two radiologists at each institution, blinded to the diagnosis, reviewed the MRIs independently and reported the presence or absence of normal marrow fat signal within the tumor based upon T1-weighted imaging without fat suppression and T2-weighted imaging with fat suppression and/or short inversion-time inversion recovery (STIR).
  • For each institution, a Fisher's exact test was used to compare the frequency of focal normal marrow fat signal in benign and malignant tumors.
  • Fisher's exact test was also used to compare the frequency of intratumoral fat in benign and malignant lesions for the pooled sample.
  • There were three discrepancies (one malignant and two benign) at site 1 and four discrepancies (two malignant and two benign) at site 2.
  • Reader consensus at site 1 identified normal marrow fat signal within 1 of 50 (2.0%) malignant and three of 14 (21.4%) benign tumors.
  • Reader consensus at site 2 identified normal marrow fat signal within three of 61 (4.9%) malignant and 14 of 59 (23.7%) benign tumors.
  • For the pooled consensus, the frequency of intratumoral fat in benign lesions (17/73, 23.3%) is significantly greater than the frequency in malignant lesions (4/111, 3.6%), p < 0.001.
  • CONCLUSION: The presence of focal normal marrow signal within a tumor is highly suggestive of a benign tumor.
  • [MeSH-major] Adipose Tissue / pathology. Bone Marrow / pathology. Bone Neoplasms / pathology. Magnetic Resonance Imaging / methods. Pelvic Bones / pathology
  • [MeSH-minor] Algorithms. Bayes Theorem. Female. Humans. Male. Neoplasm Metastasis. Predictive Value of Tests. Reproducibility of Results


77. Takahashi N, Inoue T, Lee J, Yamaguchi T, Shizukuishi K: The roles of PET and PET/CT in the diagnosis and management of prostate cancer. Oncology; 2007;72(3-4):226-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The roles of PET and PET/CT in the diagnosis and management of prostate cancer.
  • 2-(18)F-fluoro-2-deoxy-D-glucose (FDG)-positron emission tomography (PET) imaging in prostate cancer is challenging because glucose utilization in well-differentiated prostate cancer is often lower than in other tumor types.
  • On the other hand, FDG-PET is limited in the identification of prostate tumors, as normal urinary excretion of radioisotope can mask pathological uptake.
  • Moreover, there is an overlap in the degree of uptake between prostate cancer, benign prostatic hyperplasia and inflammation.
  • [MeSH-major] Bone Neoplasms / radionuclide imaging. Positron-Emission Tomography. Prostatic Neoplasms / radionuclide imaging. Prostatic Neoplasms / therapy. Radioimmunodetection. Tomography, Emission-Computed

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel
  • (PMID = 18176088.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 53
  •  go-up   go-down


78. Nyman HT, Nielsen OL, McEvoy FJ, Lee MH, Martinussen T, Hellmén E, Kristensen AT: Comparison of B-mode and Doppler ultrasonographic findings with histologic features of benign and malignant mammary tumors in dogs. Am J Vet Res; 2006 Jun;67(6):985-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of B-mode and Doppler ultrasonographic findings with histologic features of benign and malignant mammary tumors in dogs.
  • OBJECTIVE: To compare and correlate B-mode and color Doppler ultrasonographic characteristics with the histologic findings of benign and malignant mammary tumors in dogs.
  • STUDY POPULATION: 49 mammary tumors in 26 dogs.
  • PROCEDURES: Before excision, tumors were evaluated via B-mode and color Doppler ultrasonography to assess size, echogenicity, echopattern, acoustic transmission, invasiveness, and vascularity.
  • Paraffin-embedded microsections of the tumors were stained with H&E and examined for presence of necrosis, cysts, cartilage, bone, mineralization, invasion of surrounding tissue, and tissue heterogeneity.
  • RESULTS: Tumor echogenicity and echopattern on ultrasonographic images correlated with tissue heterogeneity detected histologically.
  • Tumor invasion into surrounding tissues as determined ultrasonographically did not correlate with the histologic findings.
  • There was a significant correlation between the number of detected vessels and distribution of flow within the tumors determined via ultrasonographic and histologic examinations.
  • CONCLUSIONS AND CLINICAL RELEVANCE: In canine mammary tumors, ultrasonographic characteristics appear to be correlated with histopathologic changes.
  • Data suggest that ultrasonography may have an important role in the evaluation of mammary tumors in dogs, particularly in the evaluation of tissue composition and tumor vascularity.
  • [MeSH-minor] Adenoma / diagnosis. Adenoma / ultrasonography. Adenoma / veterinary. Animals. Carcinoma / diagnosis. Carcinoma / ultrasonography. Carcinoma / veterinary. Dogs. Female. Hyperplasia / diagnosis. Hyperplasia / ultrasonography. Hyperplasia / veterinary

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16740091.001).
  • [ISSN] 0002-9645
  • [Journal-full-title] American journal of veterinary research
  • [ISO-abbreviation] Am. J. Vet. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


79. Georgy BA, Wong W: Plasma-mediated radiofrequency ablation assisted percutaneous cement injection for treating advanced malignant vertebral compression fractures. AJNR Am J Neuroradiol; 2007 Apr;28(4):700-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND PURPOSE: Using percutaneous cement injection to treat vertebral compression fractures (VCF) stemming from advanced malignancy, particularly those showing posterior cortical defect and epidural extension, is associated with higher risk of complications compared with treating benign osteoporotic VCF.
  • MATERIALS AND METHODS: A prospective series of patients (n = 15) with metastatic lesions having epidural extension of tumor and/or cortical disruption were treated.
  • The percutaneous procedure consisted of using a plasma-mediated radio-frequency-based device to etch a cavity within the affected vertebral body and filling the cavity and adjacent interstices with bone cement.
  • CONCLUSION: Dissolution of tissue rather than displacement to create a cavity before injecting bone cement permitted well-directed cement deposition into the compromised vertebral body, which may allow a safer procedure to be conducted in patients with advanced malignant VCF.
  • Clinical benefits may include avoiding more extensive surgery and reducing the risk of complications associated with conventional bone cement injection procedures.
  • [MeSH-major] Bone Cements / therapeutic use. Catheter Ablation. Fractures, Compression / therapy. Spinal Fractures / therapy. Spinal Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Spine Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17416824.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bone Cements
  •  go-up   go-down


81. van den Berg H, Slaar A, Kroon HM, Taminiau AH, Hogendoorn P: Results of diagnostic review in pediatric bone tumors and tumorlike lesions. J Pediatr Orthop; 2008 Jul-Aug;28(5):561-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of diagnostic review in pediatric bone tumors and tumorlike lesions.
  • BACKGROUND: Histological examination of bone tumors is one of the most difficult subjects in pathology.
  • In this manuscript, correctness of initial histological diagnosis in pediatric bone tumors and tumorlike lesions was investigated.
  • PROCEDURE: All 262 bone tumor specimens of children up to the age of 19 years reviewed from 1999 to 2003 by the Netherlands Committee on Bone Tumors were included.
  • Initial diagnosis and diagnosis after review were compared.
  • After classification according to the main categories of the World Health Organization classification, only 75% of tumors were correctly categorized.
  • Thirteen of the 60 malignant tumors were not recognized as malignant.
  • Seven of 198 benign lesions were reclassified as malignant.
  • Kappa values were indicative for good agreement in the (by the Ministry of Health designated) bone tumor centers.
  • Agreement was almost perfect in Ewing/primitive neuroectodermal tumors.
  • For cartilaginous, osteogenic, and fibrous tumors, agreement was lower.
  • Adamantinomas were not recognized in non-bone tumor centers.
  • For the remaining group composed of miscellaneous tumors, poor levels of agreement were noted.
  • CONCLUSIONS: We conclude that correct diagnosis of childhood bone tumors requires review by a multidisciplinary team of experts.
  • Specifically in non-bone tumor centers, the correctness of the initial diagnosis can be questioned.
  • [MeSH-major] Bone Neoplasms / pathology
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Infant. Male. Netherlands. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18580373.001).
  • [ISSN] 0271-6798
  • [Journal-full-title] Journal of pediatric orthopedics
  • [ISO-abbreviation] J Pediatr Orthop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Chung LW, Baseman A, Assikis V, Zhau HE: Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. J Urol; 2005 Jan;173(1):10-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular insights into prostate cancer progression: the missing link of tumor microenvironment.
  • PURPOSE: Tumor cell genotype and phenotype have been considered the only determinants supporting cancer growth and metastasis.
  • This review focuses on the published literature that suggests that tumor-microenvironment interaction has a decisive role in controlling local cancer growth, invasion and distant metastasis.
  • As this review shows, genetic alterations in prostate cancer cells alone are not enough to confer metastatic status without a supporting tumor microenvironment.
  • Effective therapeutic targeting requires a deeper understanding of the interplay between tumor and stroma.
  • Approaches co-targeting tumor and stroma already show promise over the conventional targeting of tumor cells alone in preventing prostate cancer progression and eradicating preexisting or newly developed prostate cancers in bone and visceral organs.
  • MATERIALS AND METHODS: A literature survey using the MEDLINE database was performed in basic and clinical publications relevant to tumor-host microenvironment interaction.
  • RESULTS: Tumor associated stroma actively fuel the progression of prostate cancer from localized growth to the invasion of surrounding tissues, and the development of distant bone and visceral organ metastasis.
  • In concert with this progression tumor cells recovered from metastatic sites could represent a subpopulation of preexisting tumor cells or could be a newly acquired variant subsequent to tumor-stromal interaction.
  • This presents a new opportunity for therapeutic targeting for the treatment of benign and malignant growth of the prostate glands.
  • This review summarizes specific research implicating tumor-microenvironment interaction as the molecular basis of cancer progression, providing a rationale for targeting tumor and the tumor associated microenvironment in the management of androgen independent and bone metastatic prostate cancer progression in patients.
  • Further elucidation of the molecular mechanisms underlying tumor-stromal interaction may yield improved medical treatments for prostate cancer growth and metastasis.
  • [MeSH-minor] Bone Neoplasms / physiopathology. Bone Neoplasms / secondary. Breast Neoplasms / physiopathology. Cell Differentiation. Cell Line, Tumor. Cell Transformation, Neoplastic. Disease Progression. Extracellular Matrix / physiology. Fibroblasts / physiology. Gene Expression Regulation, Neoplastic / physiology. Humans. Male. Molecular Mimicry. Neoplasm Invasiveness. Signal Transduction / physiology. Vascular Endothelial Growth Factor A / physiology

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15592017.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 098912; United States / NCI NIH HHS / CA / CA 76620
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A
  • [Number-of-references] 73
  •  go-up   go-down


83. García-Reyna JC, Rico Martínez G, Vega González IF, Linares LM, Delgado Cedillo EA, Romero Ramírez R: [Musculoskeletal tumor evaluation with 99mTc-Tetrofosmin]. Acta Ortop Mex; 2008 Nov-Dec;22(6):390-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Musculoskeletal tumor evaluation with 99mTc-Tetrofosmin].
  • [Transliterated title] 99mTc-Tetrofosmin en la evaluación de tumores musculoesqueléticos.
  • INTRODUCTION: (99m)Tc-tetrofosmin is an efficient agent as a tumor marker.
  • Several studies have proven its efficiency in detection and localization of tumors of the breast, larynx, thyroid, parathyroid glands, lung, brain, skin, lymphatic and musculoskeletal tissues with a sensitivity and specificity of 95% to 100%.
  • Nevertheless, benign pathology such as active inflammation is a source of false positives and the attending physician must consider the aid of complementary studies such as histopathology.
  • [MeSH-major] Bone Neoplasms / radionuclide imaging. Muscle Neoplasms / radionuclide imaging. Organophosphorus Compounds. Organotechnetium Compounds. Radiopharmaceuticals

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19280840.001).
  • [ISSN] 2306-4102
  • [Journal-full-title] Acta ortopédica mexicana
  • [ISO-abbreviation] Acta Ortop Mex
  • [Language] spa
  • [Publication-type] Clinical Trial; Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Mexico
  • [Chemical-registry-number] 0 / Organophosphorus Compounds; 0 / Organotechnetium Compounds; 0 / Radiopharmaceuticals; 0 / technetium Tc 99m 1,2-bis(bis(2-ethoxyethyl)phosphino)ethane
  •  go-up   go-down


84. Vergara HF, Ortiz DA, Martínez BH, Mosiñoz RM, Arellano JA: [Hand reconstructive surgery secondary to giant cell tumor]. Acta Ortop Mex; 2010 Sep-Oct;24(5):345-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hand reconstructive surgery secondary to giant cell tumor].
  • [Transliterated title] Cirugía reconstructiva de mano secundario a tumor de células gigantes.
  • The giant cell tumor of the bone is a neoplastic low grade lesion that usually appears in the epiphyseal or metaphyseal region of the long bones.
  • The lesion is usually solitary and becomes symptomatic when a considerable proportion of the bone has been destroyed.
  • It is thought to represent approximately 19% of the benign bone tumors and 9% of all the primary bone tumors, according to a review by Schajowicz.
  • The treatment of the giant cell tumor is controversial and the literature is confusing.
  • The giant cell tumor is located mainly in the hand.
  • Its potential aggressiveness makes us consider it in the differential diagnosis of the tumor lesions affecting the hand.
  • The purpose of this research work is to describe our experience with the treatment of the giant cell tumor in three cases that presented as a lytic, expansive lesion affecting the bones of the hand.
  • They were treated with tumor resection and a bone graft to fill the defect.
  • [MeSH-major] Bone Neoplasms / surgery. Finger Phalanges. Giant Cell Tumor of Bone / surgery

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21246807.001).
  • [ISSN] 2306-4102
  • [Journal-full-title] Acta ortopédica mexicana
  • [ISO-abbreviation] Acta Ortop Mex
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


85. Gratzinger D, Zhao S, West R, Rouse RV, Vogel H, Gil EC, Levy R, Lossos IS, Natkunam Y: The transcription factor LMO2 is a robust marker of vascular endothelium and vascular neoplasms and selected other entities. Am J Clin Pathol; 2009 Feb;131(2):264-78
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The transcription factor LMO2 is involved in vascular and hematopoietic development and hematolymphoid neoplasia.
  • LMO2 is uniformly expressed in benign vascular and lymphatic neoplasms and in most malignant vascular neoplasms with the exception of epithelioid vascular neoplasms of pleura and bone.
  • Among nonvascular neoplasms, LMO2 reactivity is present in giant cell tumor of tendon sheath, juvenile xanthogranuloma, a subset of gastrointestinal stromal tumors, small round blue cell tumors, and myoepithelial-derived neoplasms.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19141387.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA034233; United States / NCI NIH HHS / CA / CA34233; United States / NCI NIH HHS / CA / CA122105; United States / NCI NIH HHS / CA / CA33399; United States / NCI NIH HHS / CA / R37 CA033399; United States / NCI NIH HHS / CA / R01 CA109335; United States / NCI NIH HHS / CA / R01 CA122105; United States / NCI NIH HHS / CA / CA109335; United States / NCI NIH HHS / CA / P30 CA124435
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / LIM Domain Proteins; 0 / LMO2 protein, human; 0 / Metalloproteins; 0 / Proto-Oncogene Proteins
  • [Other-IDs] NLM/ NIHMS636776; NLM/ PMC4305438
  •  go-up   go-down


86. Guo Z, Wang Z, Li J, Li XD: [Reconstruction with a new type of combined reconstruction following excision of periacetabular tumors]. Zhonghua Wai Ke Za Zhi; 2008 Jun 15;46(12):895-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Reconstruction with a new type of combined reconstruction following excision of periacetabular tumors].
  • OBJECTIVE: To evaluate the reconstructive effect of a new pattern of combined reconstruction after periacetabular tumor resections.
  • METHODS: Between March 2001 and March 2007, tumor resections and new pattern of combined reconstructions which consisted of screw-rod system, acetabular reinforcement shell, antibiotic cement and total hip arthroplasty techniques were performed in 23 patients with periacetabular tumors.
  • Seventeen patients had primary malignant tumors including 7 chondrosarcomas, 4 osteosarcomas, 2 Ewing sarcomas, 2 malignant fibrohistiocytomas, 1 malignant Schwannomas, and 1 synovial sarcoma.
  • Other primary tumors were 2 giant cell tumors and 1 aggressive osteoblastoma.
  • Three metastatic bone tumors were also included in this study, and the original sites were thyroid, breast, and ovary.
  • Three primary benign bone tumors belonged to stage III.
  • 8 months (range, 9-73 months) in the patients with primary tumors.
  • CONCLUSIONS: This new combined reconstruction is an effective way to rebuild pelvic ring and maintain hip function with low complication rate after periacetabular tumor resections.
  • [MeSH-major] Acetabulum. Bone Neoplasms / surgery. Reconstructive Surgical Procedures / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Arthroplasty, Replacement, Hip. Bone Screws. Female. Follow-Up Studies. Humans. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19035146.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


87. Prado MP, Mendes AA, Amodio DT: Benign bone tumors subperiosteal on the talar neck resected anthroscopically: case reports. Einstein (Sao Paulo); 2010 Sep;8(3):354-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign bone tumors subperiosteal on the talar neck resected anthroscopically: case reports.
  • Two cases of benign chondral tumors of the talar neck region (an osteoid osteoma and a chondroblastoma) were described.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 26760154.001).
  • [ISSN] 1679-4508
  • [Journal-full-title] Einstein (São Paulo, Brazil)
  • [ISO-abbreviation] Einstein (Sao Paulo)
  • [Language] eng; por
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


88. Theocharis AD, Seidel C, Borset M, Dobra K, Baykov V, Labropoulou V, Kanakis I, Dalas E, Karamanos NK, Sundan A, Hjerpe A: Serglycin constitutively secreted by myeloma plasma cells is a potent inhibitor of bone mineralization in vitro. J Biol Chem; 2006 Nov 17;281(46):35116-28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serglycin constitutively secreted by myeloma plasma cells is a potent inhibitor of bone mineralization in vitro.
  • Immunohistochemical staining of bone marrow biopsies showed the presence of serglycin both in benign and malignant plasma cells.
  • Immunoblotting in bone marrow aspirates from a limited number of patients with newly diagnosed MM revealed highly increased levels of serglycin in 30% of the cases.
  • Serglycin isolated from myeloma plasma cells was found to influence the bone mineralization process through inhibition of the crystal growth rate of hydroxyapatite.
  • [MeSH-minor] Cell Line, Tumor. Durapatite / chemistry. Durapatite / metabolism. Humans. Protein Conformation

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • Hazardous Substances Data Bank. HYDROXYAPATITE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16870619.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proteoglycans; 0 / Vesicular Transport Proteins; 0 / serglycin; 91D9GV0Z28 / Durapatite
  •  go-up   go-down


89. Shigematsu K, Kobata Y, Yajima H, Kawamura K, Maegawa N, Takakura Y: Giant-cell tumors of the carpus. J Hand Surg Am; 2006 Sep;31(7):1214-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant-cell tumors of the carpus.
  • Giant cell tumor (GCT) of bone is a rare, benign tumor with some aggressive characteristics such as a high recurrence rate.
  • The tumor usually occurs in the distal radius although it has been reported in the carpus.
  • We reviewed 63 manuscripts published from 1935 to 2005 and report on the treatment of GCT of carpal bone in 29 cases.
  • [MeSH-major] Bone Neoplasms / surgery. Carpal Bones / surgery. Giant Cell Tumor of Bone / surgery
  • [MeSH-minor] Amputation. Bone Transplantation. Cryosurgery. Curettage. Humans. Neoplasm Recurrence, Local

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16945730.001).
  • [ISSN] 0363-5023
  • [Journal-full-title] The Journal of hand surgery
  • [ISO-abbreviation] J Hand Surg Am
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 38
  •  go-up   go-down


90. Doak SH, Jenkins SA, Hurle RA, Varma M, Hawizy A, Kynaston HG, Parry JM: Bone morphogenic factor gene dosage abnormalities in prostatic intraepithelial neoplasia and prostate cancer. Cancer Genet Cytogenet; 2007 Jul 15;176(2):161-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone morphogenic factor gene dosage abnormalities in prostatic intraepithelial neoplasia and prostate cancer.
  • Abnormal expression of bone morphogenic proteins (BMP) has been reported in prostate cancer as compared to benign prostatic tissue.
  • Probes for fluorescence in situ hybridization for the BMP, BMP5, BMP7, and UC28 gene loci were developed and applied to archival sections with areas of adjacent benign epithelium, high-grade prostatic intraepithelial neoplasia, and prostate carcinoma.
  • No deletions of the gene loci examined were observed, but gain of BMP2, BMP5, BMP7, and UC28 occurred in 58, 50, 50, and 67% of tumor foci, respectively.
  • These aberrations in copy number may be caused by early events in tumor development because they were also present in 10-30% of high-grade prostatic intraepithelial hyperplasia foci.
  • In addition, one tumor demonstrated a tandem amplification of the UC28 gene locus.
  • Approximately half of the prostate tumors displayed increased copy numbers of the BMP2, BMP5, BMP7, and UC28 gene loci, which may account for their abnormal gene expression patterns in neoplastic prostate tissue.
  • [MeSH-major] Bone Morphogenetic Proteins / genetics. Gene Dosage. Prostatic Intraepithelial Neoplasia / genetics. Prostatic Neoplasms / genetics
  • [MeSH-minor] Aged. Bone Morphogenetic Protein 2. Bone Morphogenetic Protein 5. Bone Morphogenetic Protein 7. Cell Nucleus / metabolism. Gene Expression Regulation, Neoplastic. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Neoplasm Proteins / genetics. Neoplasm Proteins / metabolism. Neoplasm Staging. Transforming Growth Factor beta / genetics. Transforming Growth Factor beta / metabolism

  • Genetic Alliance. consumer health - Bone Cancer.
  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17656261.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BMP2 protein, human; 0 / BMP5 protein, human; 0 / BMP7 protein, human; 0 / Bone Morphogenetic Protein 2; 0 / Bone Morphogenetic Protein 5; 0 / Bone Morphogenetic Protein 7; 0 / Bone Morphogenetic Proteins; 0 / Neoplasm Proteins; 0 / PBOV1 protein, human; 0 / Transforming Growth Factor beta
  •  go-up   go-down


91. Tanigawa N, Kariya S, Kojima H, Komemushi A, Fujii H, Sawada S: Lower limb ischaemia caused by fractured osteochondroma of the femur. Br J Radiol; 2007 Apr;80(952):e78-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Osteochondroma is the most common benign bone tumour and can arise in any bone.
  • [MeSH-major] Bone Neoplasms / complications. Exostoses, Multiple Hereditary / complications. Femoral Fractures / complications. Ischemia / etiology. Leg / blood supply


92. Boudewyns AN, van Dinther JJ, Colpaert CG: Sinonasal fibro-osseous hamartoma: case presentation and differential diagnosis with other fibro-osseous lesions involving the paranasal sinuses. Eur Arch Otorhinolaryngol; 2006 Mar;263(3):276-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sinonasal fibro-osseous hamartoma: case presentation and differential diagnosis with other fibro-osseous lesions involving the paranasal sinuses.
  • A combination of clinical, radiographic and histological information permitted a diagnosis of a benign fibro-osseous lesion: sinonasal hamartoma.
  • The benign nature of this tumor justified a conservative follow-up.
  • [MeSH-major] Fibroma, Ossifying / diagnosis. Hamartoma / diagnosis. Paranasal Sinus Diseases / diagnosis
  • [MeSH-minor] Biopsy. Bone Neoplasms / diagnosis. Child, Preschool. Diagnosis, Differential. Female. Fibrous Dysplasia of Bone / diagnosis. Hearing Loss / etiology. Humans. Nasal Obstruction / etiology. Nasal Obstruction / pathology. Osteoma / diagnosis. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Otorhinolaryngol Belg. 1994;48(1):37-40 [8171999.001]
  • [Cites] Am J Rhinol. 1999 Mar-Apr;13(2):111-6 [10219439.001]
  • [Cites] J Oral Maxillofac Surg. 1993 Aug;51(8):828-35 [8336219.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 2004 Mar;68(3):359-64 [15129948.001]
  • [Cites] Br Med J. 1968 Aug 3;3(5613):267-72 [5661665.001]
  • [Cites] Am J Surg Pathol. 1998 Apr;22(4):425-33 [9537469.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1984 May-Jun;93(3 Pt 1):199-203 [6732102.001]
  • [Cites] Int J Oral Maxillofac Surg. 1995 Apr;24(2):162-9 [7608584.001]
  • [Cites] Adv Anat Pathol. 2001 May;8(3):126-43 [11345237.001]
  • [Cites] J Laryngol Otol. 1973 Aug;87(8):801-5 [4729963.001]
  • [Cites] Am J Clin Pathol. 2002 Dec;118 Suppl:S50-70 [14569813.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 2005 Jan;69(1):87-91 [15627453.001]
  • (PMID = 16283200.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


93. Ozan F, Toker G: Secondary aneurysmal bone cyst of the patella. Acta Orthop Traumatol Turc; 2010;44(3):246-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary aneurysmal bone cyst of the patella.
  • Aneurysmal bone cyst accounts for 1% of primary bone tumors and is one of the benign tumor-like lesions.
  • Its development on the basis of any previous lesion such as chondroblastoma is called secondary aneurysmal bone cyst.
  • Radiological studies were suggestive of an aneurysmal bone cyst.
  • At surgery, the cystic lesion was removed via curettage and the residual cavity was filled with an autogenous bone graft taken from the iliac wing.
  • The histopathologic diagnosis was secondary aneurysmal bone cyst in association with chondroblastoma.
  • [MeSH-major] Bone Cysts, Aneurysmal / radiography. Bone Neoplasms / complications. Chondroblastoma / complications. Patella
  • [MeSH-minor] Adult. Bone Transplantation. Curettage. Humans. Ilium / transplantation. Male

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21088467.001).
  • [ISSN] 1017-995X
  • [Journal-full-title] Acta orthopaedica et traumatologica turcica
  • [ISO-abbreviation] Acta Orthop Traumatol Turc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


94. Leto G, Incorvaia L, Badalamenti G, Tumminello FM, Gebbia N, Flandina C, Crescimanno M, Rini G: Activin A circulating levels in patients with bone metastasis from breast or prostate cancer. Clin Exp Metastasis; 2006;23(2):117-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activin A circulating levels in patients with bone metastasis from breast or prostate cancer.
  • Therefore, we have investigated the clinical significance of its circulating levels in patients with bone metastasis.
  • Activin A serum concentrations were determined, by a commercially available enzyme-linked immunosorbent assay kit, in 72 patients with breast cancer (BC) or prostatic cancer (PC) with (BM+) or without (BM-) bone metastases, in 15 female patients with age-related osteoporosis (OP), in 20 patients with benign prostatic hypertrophy (BPH) and in 48 registered healthy blood donors (HS) of both sex (25 female and 23 male).
  • In BC patients, a significant correlation was observed only between Activin A and number of bone metastases (P = 0.0065) while, in PC patients, Activin A levels were strongly correlated with the Gleason score (P = 0.011) or PSA levels (P = 0.0001) and, to a lessen extent, with the number of bone metastases (P = 0.056).
  • These findings indicate that Activin A may be implicated in the pathogenesis of bone metastasis.
  • Therefore, this cytokine may be considered a novel potential target for a more selective therapeutic approach in the treatment of skeletal metastasis and may be also useful as additional biochemical marker of metastatic bone disease.
  • [MeSH-major] Activins / blood. Bone Neoplasms / secondary. Breast Neoplasms / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Female. Humans. Male. Middle Aged. Osteoporosis / blood. Prostatic Hyperplasia / blood. Sensitivity and Specificity


95. Fayad LM, Bluemke DA, McCarthy EF, Weber KL, Barker PB, Jacobs MA: Musculoskeletal tumors: use of proton MR spectroscopic imaging for characterization. J Magn Reson Imaging; 2006 Jan;23(1):23-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Musculoskeletal tumors: use of proton MR spectroscopic imaging for characterization.
  • PURPOSE: To determine the value of multivoxel proton magnetic resonance spectroscopic imaging (MRSI) in distinguishing malignant skeletal tumors from benign tumors and normal bone marrow using the metabolite choline (Cho) as a marker for malignancy.
  • MATERIALS AND METHODS: Pathologic specimens obtained from 13 patients who had undergone wide resection for skeletal tumors underwent evaluation by MRSI at 1.5 T.
  • Cho SNRs were compared between areas containing malignant tumor and nonmalignant tissue (benign lesion or normal bone marrow) as determined by histopathology.
  • All specimens included a sample of normal bone marrow and two specimens also contained benign lesions.
  • CONCLUSION: These preliminary results indicate that MRSI at 1.5 T is a promising noninvasive method of differentiating malignant skeletal tumors from nonmalignant tissue.
  • Using MRSI, Cho can be detected in skeletal tumors and may serve as a marker for malignancy.

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CHOLINE CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16315208.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA100184; United States / NCI NIH HHS / CA / 1R01CA100184; United States / NCI NIH HHS / CA / P50CA103175
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protons; N91BDP6H0X / Choline
  •  go-up   go-down


96. Urbánová A, Janega P, Masárová K, Stefániková Z, Babál P: [Immunohistochemical detection of ZAP-70 protein and its importance in the diagnostics of B-CLL]. Cesk Patol; 2009 Apr;45(2):40-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is known for its variable course--from benign to prospectless forms.
  • Reliable prognostic markers are needed to precify the diagnosis and the correct therapy.
  • The present study includes 20 cases of bone marrow trephine biopsy from patients with diagnosed B-CLL and 20 control cases without neoplastic infiltration.
  • [MeSH-major] Biomarkers, Tumor / analysis. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. ZAP-70 Protein-Tyrosine Kinase / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19534392.001).
  • [ISSN] 1210-7875
  • [Journal-full-title] Československá patologie
  • [ISO-abbreviation] Cesk Patol
  • [Language] slo
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase; EC 2.7.10.2 / ZAP70 protein, human
  •  go-up   go-down


97. Boulos PR, Knoepp SM, Rubin PA: Green bone. Arch Ophthalmol; 2007 Mar;125(3):380-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Green bone.
  • OBJECTIVE: To describe the unusual finding of yellow-green-colored bone during routine orbital surgery, to detail its investigation, and to demonstrate its benign nature.
  • METHODS: When green bone was found, specimens were sent for light and fluorescent microscopy, ultraviolet photography, and spectrophotometry.
  • RESULTS: Yellow-green bone was encountered in 3 patients during orbital tumor excision or orbital fracture repair procedures.
  • In all cases, absence of neoplasia was demonstrated histologically.
  • The bone fluoresced with a bright yellow-green color when exposed to 365-nm ultraviolet light.
  • CONCLUSIONS: Fixation of tetracycline and ensuing fluorescence occurs mostly in areas of new bone growth and mineralization.
  • This happens during childhood but also with bone remodeling associated with tumors or fractures.
  • This paucity of external clues can lead to the surprising but innocuous surgical finding of green bone.

  • Hazardous Substances Data Bank. TETRACYCLINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17353410.001).
  • [ISSN] 0003-9950
  • [Journal-full-title] Archives of ophthalmology (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Synthesis Inhibitors; F8VB5M810T / Tetracycline
  •  go-up   go-down


98. Papadaki ME, Troulis MJ, Kaban LB: Advances in diagnosis and management of fibro-osseous lesions. Oral Maxillofac Surg Clin North Am; 2005 Nov;17(4):415-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in diagnosis and management of fibro-osseous lesions.
  • Fibro-osseous lesions are benign mesenchymal skeletal tumors in which mineralized tissue, blood vessels, and giant cells in varying proportions replace normal bone.
  • Although fibro-osseous lesions have similar histologic and radiographic features, they may exhibit a wide range of biologic behaviors.
  • Because the histologic appearance does not predict the rate of growth or prognosis, treatment is based on the clinical and biologic behavior of the tumor.
  • The purpose of this article is to describe advances in diagnosis and management of fibro-osseous lesions.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18088796.001).
  • [ISSN] 1042-3699
  • [Journal-full-title] Oral and maxillofacial surgery clinics of North America
  • [ISO-abbreviation] Oral Maxillofac Surg Clin North Am
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Oommen AT, Madhuri V, Walter NM: Benign tumors and tumor-like lesions of the calcaneum: a study of 12 cases. Indian J Cancer; 2009 Jul-Sep;46(3):234-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign tumors and tumor-like lesions of the calcaneum: a study of 12 cases.
  • Benign tumors of the calcaneum are rare.
  • Cystic lesions such as simple bone cysts and aneurysmal bone cysts are commonly seen.
  • AIMS AND OBJECTIVES: To evaluate tumors of the calcaneum, which were seen over a 12-year period.
  • MATERIALS AND METHODS: We analyzed noninfectious, noninflammatory, benign lesions of the calcaneum seen in the Orthopedic Out Patient Department from 1991 to 2003.
  • Twelve such tumors were encountered.
  • One of the coauthors reviewed the histopathologic findings of all the tumors.
  • RESULTS: Twelve benign lesions were seen in 12 patients.
  • In our series, cysts predominated, with three aneurysmal bone cysts and five simple bone cysts.
  • The other benign tumors were: one fibrous dysplasia, one vascular hamartoma, one osteoblastoma, and one chondromyxoid fibroma.
  • The bone cysts were treated by curettage, with or without bone grafting, except for one large aneurysmal bone cyst, which was treated by excision of the calcaneum.
  • CONCLUSION: The calcaneum is an uncommon site for most bone tumors, and in our series, bone cysts were the most common benign lesions.
  • Curettage and bone grafting or the use of bone substitutes can be effectively used in the treatment of symptomatic bone cysts of the calcaneum.
  • [MeSH-major] Bone Cysts / pathology. Bone Cysts, Aneurysmal / pathology. Bone Neoplasms / pathology. Calcaneus / pathology. Osteoblastoma / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19574677.001).
  • [ISSN] 0019-509X
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


100. Schindler OS, Cannon SR, Briggs TW, Blunn GW: Composite ceramic bone graft substitute in the treatment of locally aggressive benign bone tumours. J Orthop Surg (Hong Kong); 2008 Apr;16(1):66-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Composite ceramic bone graft substitute in the treatment of locally aggressive benign bone tumours.
  • PURPOSE: To report the use of a composite ceramic bone graft substitute containing calcium sulphate and hydroxyapatite (HA) in the treatment of large expansive osteolytic benign bone tumours.
  • METHODS: 4 women and 9 men aged 8 to 49 (mean, 22) years with aneurysmal bone cysts (n=6) or giant cell tumours (n=7) in the epi- or meta-physeal areas of the lower limbs underwent curettage, phenolisation, and filling with bone graft substitute containing calcium sulphate and HA.
  • The mean tumour size was 38.5 (range, 18-65) ml.
  • Range of movement, Musculoskeletal Tumor Society Rating Score (MTSRS), and haematological and blood biochemical parameters were measured.
  • RESULTS: Two patients had recurrence at 7 and 9 months, both progressed to grade-III giant cell tumours.
  • CONCLUSION: Composite bioceramic osteoconductive grafts, which combine porous HA with calcium sulphate, provide a framework for human osteogenesis and avoid donor-site morbidity (autologous bone graft harvesting).
  • Tumour recurrence remains a major concern especially in young patients, as revision invariably requires removal of additional bone, potentially compromising joint integrity.
  • [MeSH-major] Bone Cysts, Aneurysmal / surgery. Bone Neoplasms / surgery. Bone Substitutes / therapeutic use. Ceramics / therapeutic use. Durapatite / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Child. Female. Femoral Neoplasms / surgery. Giant Cell Tumor of Bone / surgery. Humans. Male. Middle Aged. Tibia / surgery

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYDROXYAPATITE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18453663.001).
  • [ISSN] 1022-5536
  • [Journal-full-title] Journal of orthopaedic surgery (Hong Kong)
  • [ISO-abbreviation] J Orthop Surg (Hong Kong)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bone Substitutes; 91D9GV0Z28 / Durapatite
  •  go-up   go-down






Advertisement